{"content":"<li class=\"n-box-item date-title\" data-end=\"1529035199\" data-start=\"1528948800\" data-txt=\"Monday, December 23, 2019\">Thursday, June 14, 2018</li><li class=\"n-box-item sa-box-item\" data-id=\"3364124\" data-ts=\"1529015814\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NXPI\" target=\"_blank\">NXPI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3364124-nxpplus-8_3-on-report-china-okd-qualcomm-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NXP +8.3% on report China has OK&#39;d Qualcomm deal</a></h4><ul>   <li>NXP Semiconductors (NASDAQ:<a href='https://seekingalpha.com/symbol/NXPI' title='NXP Semiconductors'>NXPI</a>) is jumping after hours, <font color='green'>up 8.3%</font>, as the <i>South China Morning Post</i> reports that Chinese regulators have <a href=\"http://www.scmp.com/business/companies/article/2150894/chinese-regulators-approve-qualcomm-purchase-nxp-us44-billion\" target=\"_blank\">approved Qualcomm's $44B buyout</a> of the company.</li>    <li>Qualcomm (NASDAQ:<a href='https://seekingalpha.com/symbol/QCOM' title='Qualcomm Inc.'>QCOM</a>) is <font color='green'>up 2.2%</font> after hours.</li><li>That clears the final hurdle, according to the report, as China is the last of nine nations that had to sign off on the merger.</li><li>But timing of the deal, or what assets Qualcomm might have agreed to give up to seal it, are still unknown.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3363346-nxp-semiconductors-minus-1_8-percent-senate-pushback-zte-ban-lift\" target=\"_blank\">NXP Semiconductors -1.8% after Senate pushback on ZTE ban lift</a> (Jun. 12 2018)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3362738-qualcomm-extends-tender-offer-nxp-tendered-shares-drop\" target=\"_blank\">Qualcomm extends tender offer for NXP, tendered shares drop</a> (Jun. 08 2018)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3364124\" data-linked=\"NXP +8.3% on report China has OK&#39;d Qualcomm deal\" data-tweet=\"$NXPI $NXPI $QCOM - NXP +8.3% on report China has OK&#39;d Qualcomm deal https://seekingalpha.com/news/3364124-nxpplus-8_3-on-report-china-okd-qualcomm-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3364124-nxpplus-8_3-on-report-china-okd-qualcomm-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:36 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>131&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3364121\" data-ts=\"1529014694\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GSAT\" target=\"_blank\">GSAT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3364121-globalstar-ordered-to-produce-witness-in-merger-suit\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Globalstar ordered to produce witness in merger suit</a></h4><ul>   <li>Globalstar (NYSEMKT:<a href='https://seekingalpha.com/symbol/GSAT' title='Globalstar, Inc.'>GSAT</a>) has been ordered to produce a witness for a June 21 deposition in a lawsuit filed by one of its investors, Bloomberg reports.</li>    <li>Shares are <font color='red'>2.3% lower</font> after hours.</li>    <li>Jason Mudrick and Mudrick Capital Management <a href=\"https://seekingalpha.com/news/3358004-mudrick-sues-globalstar-look-books-merger\" target=\"_blank\">sued the company</a> in May over a planned merger with FiberLight and other assets also controlled by Globalstar chief Jay Monroe, calling it a \"self-dealing\" transaction.</li>    <li>Mudrick had <a href=\"https://seekingalpha.com/news/3345104-globalstar-plus-6_4-percent-mudrick-goes-active-stake-offers-150m-financing\" target=\"_blank\">converted into an activist investor</a> the month before, on a quest to prevent the company from taking additional financing from Monroe's Thermo Companies.</li>    <li>Mudrick now says it needs a witness for the \"limited purpose of testifying to the existence and volume of the documents sought in plaintiff&rsquo;s demand.\"</li> </ul><div class=\"tiny-share-widget\" data-id=\"3364121\" data-linked=\"Globalstar ordered to produce witness in merger suit\" data-tweet=\"$GSAT - Globalstar ordered to produce witness in merger suit https://seekingalpha.com/news/3364121-globalstar-ordered-to-produce-witness-in-merger-suit?source=tweet\" data-url=\"https://seekingalpha.com/news/3364121-globalstar-ordered-to-produce-witness-in-merger-suit\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:18 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3364116\" data-ts=\"1529012103\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VSTM\" target=\"_blank\">VSTM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3364116-after-hours-gainers-losers-06-14-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers (06/14/2018)</a></h4><ul>     <li><b>Top gainers:</b>&nbsp;<a href='https://seekingalpha.com/symbol/VSTM' title='Verastem, Inc.'>VSTM</a>&nbsp;<font color='green'>+6.5%</font>. <a href='https://seekingalpha.com/symbol/VNCE' title='Vince Holding Corp.'>VNCE</a>&nbsp;<font color='green'>+3.5%</font>. <a href='https://seekingalpha.com/symbol/HUYA' title='Huya Broadcasting'>HUYA</a> <font color='green'>+3.3%</font>. <a href='https://seekingalpha.com/symbol/BRFS' title='BRF-Brasil Foods S.A.'>BRFS</a>&nbsp;<font color='green'>+3.0%</font>. <a href='https://seekingalpha.com/symbol/KB' title='KB Financial Group Inc.'>KB</a> <font color='green'>+2.4%</font>.</li>     <li><strong>Top Losers:&nbsp;</strong><a href='https://seekingalpha.com/symbol/DEST' title='Destination Maternity Corporation'>DEST</a> <font color='red'>-3.7%</font>. <a href='https://seekingalpha.com/symbol/ADBE' title='Adobe Systems Incorporated'>ADBE</a>&nbsp;<font color='red'>-3.4%</font>.&nbsp;&nbsp;<a href='https://seekingalpha.com/symbol/AI' title='Arlington Asset Investment Corporation'>AI</a>&nbsp;<font color='red'>-2.8%.&nbsp;</font><a href='https://seekingalpha.com/symbol/EQS' title='Equus Total Return'>EQS</a>&nbsp;<font color='red'>-2.1%</font>. <a href='https://seekingalpha.com/symbol/APRN' title='Blue Apron Holdings, Inc.'>APRN</a>&nbsp;<font color='red'>-1.6%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3364116\" data-linked=\"After Hours Gainers / Losers (06/14/2018)\" data-tweet=\"$VSTM $VSTM $VNCE - After Hours Gainers / Losers (06/14/2018) https://seekingalpha.com/news/3364116-after-hours-gainers-losers-06-14-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3364116-after-hours-gainers-losers-06-14-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:35 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3364109\" data-ts=\"1529011326\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TWX\" target=\"_blank\">TWX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3364109-time-warnerplus-1_5-u-s-wont-seek-stay-on-and-t-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Time Warner +1.5% as U.S. won&#39;t seek stay on AT&amp;T deal</a></h4><ul>    <li>Time Warner (NYSE:<a href='https://seekingalpha.com/symbol/TWX' title='Time Warner Inc.'>TWX</a>) has <font color='green'>jumped 1.5%</font> postmarket as AT&amp;T notes in a court order that the U.S. won't seek a stay to prevent its $85B buyout from closing, Bloomberg reports.</li>    <li>The two sides are agreeing to end the waiting period in order to get the deal closed.</li>    <li>In the filing, AT&amp;T says it won't have a role in setting pricing at Time Warner's Turner networks -- a sticking point in the government's antitrust trial -- and that it will manage Turner as a separate business unit.</li>    <li>Dozens of blocks of Time Warner shares have moved around the current postmarket quote of $100.28.</li>    <li>In late trading, <a href='https://seekingalpha.com/symbol/T' title='AT&T Inc.'>T</a> is <font color='red'>down 0.1%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3364109\" data-linked=\"Time Warner +1.5% as U.S. won&#39;t seek stay on AT&amp;T deal\" data-tweet=\"$TWX $TWX $T - Time Warner +1.5% as U.S. won&#39;t seek stay on AT&amp;T deal https://seekingalpha.com/news/3364109-time-warnerplus-1_5-u-s-wont-seek-stay-on-and-t-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3364109-time-warnerplus-1_5-u-s-wont-seek-stay-on-and-t-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:22 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>87&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3364098\" data-ts=\"1529009588\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CHMA\" target=\"_blank\">CHMA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3364098-chiasma-halfway-in-late-stage-study-of-octreotide-in-acromegaly-shares-up-6-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Chiasma halfway there in late-stage study of octreotide in acromegaly; shares up 6% after hours</a></h4><ul><li>Thinly traded nano cap Chiasma (NASDAQ:<a href='https://seekingalpha.com/symbol/CHMA' title='Chiasma'>CHMA</a>) is up&nbsp;<font color='green'>6%</font>&nbsp;after hours on light volume on the heels of its <a href=\"https://seekingalpha.com/pr/17192887-chiasma-achieves-50-percent-target-patients-randomized-chiasma-optimal-phase-3-clinical-trial\" target=\"_blank\">announcement</a> that its Phase 3 clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT03252353?lead=chiasma&amp;phase=2&amp;rank=1\" target=\"_blank\">OPTIMAL</a>, is 50% enrolled.&nbsp;The study is assessing octreotide capsules in adults with acromegaly.</li><li>Randomization should be completed by year-end with topline data expected in Q4 2019.</li></ul><div class=\"tiny-share-widget\" data-id=\"3364098\" data-linked=\"Chiasma halfway there in late-stage study of octreotide in acromegaly; shares up 6% after hours\" data-tweet=\"$CHMA - Chiasma halfway there in late-stage study of octreotide in acromegaly; shares up 6% after hours https://seekingalpha.com/news/3364098-chiasma-halfway-in-late-stage-study-of-octreotide-in-acromegaly-shares-up-6-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3364098-chiasma-halfway-in-late-stage-study-of-octreotide-in-acromegaly-shares-up-6-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:53 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3364095\" data-ts=\"1529009515\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ROX\" target=\"_blank\">ROX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3364095-castle-brands-misses-0_01-misses-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Castle Brands misses by $0.01, misses on revenue</a></h4><ul><li>Castle Brands (NYSEMKT:<a href='https://seekingalpha.com/symbol/ROX' title='Castle Brands Inc'>ROX</a>): Q4 EPS of $0.00 <font color='red'>misses by $0.01</font>.</li><li>Revenue of $24.07M (+6.6% Y/Y) <font color='red'>misses by $0.4M</font>.</li><li>Shares <font color='green'>+1.57%</font>.</li><li><a href='https://seekingalpha.com/pr/17192973-castle-brands-announces-fourth-quarter-fiscal-2018-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3364095\" data-linked=\"Castle Brands misses by $0.01, misses on revenue\" data-tweet=\"$ROX - Castle Brands misses by $0.01, misses on revenue https://seekingalpha.com/news/3364095-castle-brands-misses-0_01-misses-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3364095-castle-brands-misses-0_01-misses-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:51 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3364092\" data-ts=\"1529009210\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VSTM\" target=\"_blank\">VSTM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3364092-verastem-to-raise-43m-via-direct-stock-sale-shares-up-6-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Verastem to raise $43M via direct stock sale; shares up 6% after hours</a></h4><ul><li>Verastem (NASDAQ:<a href='https://seekingalpha.com/symbol/VSTM' title='Verastem, Inc.'>VSTM</a>) is up&nbsp;<font color='green'>6%</font>&nbsp;after hours in response to its <a href=\"https://seekingalpha.com/pr/17192872-verastem-oncology-announces-43_0-million-offering-common-stock\" target=\"_blank\">planned direct sale</a> of ~7.2M common shares at $6.00 per share to funds managed by Consonance Capital. Gross proceeds will be ~$43M. Closing date is June 18.</li><li>Today's close was $5.58.</li></ul><div class=\"tiny-share-widget\" data-id=\"3364092\" data-linked=\"Verastem to raise $43M via direct stock sale; shares up 6% after hours\" data-tweet=\"$VSTM - Verastem to raise $43M via direct stock sale; shares up 6% after hours https://seekingalpha.com/news/3364092-verastem-to-raise-43m-via-direct-stock-sale-shares-up-6-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3364092-verastem-to-raise-43m-via-direct-stock-sale-shares-up-6-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:46 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>24&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3364091\" data-ts=\"1529008902\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JBL\" target=\"_blank\">JBL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3364091-jabilplus-2_3-on-q3-beats-upside-revenue-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Jabil +2.3% on Q3 beats, upside revenue guidance</a></h4><ul><li>        Jabil (NYSE:<a href='https://seekingalpha.com/symbol/JBL' title='Jabil Inc.'>JBL</a>) shares are&nbsp;<font color='green'>up 2.3%</font>&nbsp;aftermarket on Q3 results that beat EPS and revenue estimates with a 21% Y/Y revenue growth. Q4 guidance has upside revenue of $5.2B to $5.6B (consensus: $5.19B) and in-line EPS of $0.56 to $0.80 (consensus: $0.68).</li><li>               Key metrics: Cash flow from operating activities, $144M; cash and equivalents, $677.5M; SG&amp;A spend, $252.5M; R&amp;D spend, $10.1M.&nbsp;</li><li>               Share repurchase: Jabil&rsquo;s board approves an additional repurchase program of up to $350M in common stock. Authorization expires August 31, 2019.&nbsp;</li><li>               Earnings call was scheduled for 4:30 PM Eastern with a webcast/replay available <a href=\"https://www.jabil.com/\" target=\"_blank\">here</a>.&nbsp;</li><li>               <a href=\"https://seekingalpha.com/pr/17192893-jabil-posts-third-quarter-results\" target=\"_blank\">Press release</a>.&nbsp;&nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3364050-jabil-beats-0_01-beats-revenue\" target=\"_blank\">Jabil beats by $0.01, beats on revenue</a> (June 14)</li></ul><div class=\"tiny-share-widget\" data-id=\"3364091\" data-linked=\"Jabil +2.3% on Q3 beats, upside revenue guidance\" data-tweet=\"$JBL - Jabil +2.3% on Q3 beats, upside revenue guidance https://seekingalpha.com/news/3364091-jabilplus-2_3-on-q3-beats-upside-revenue-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3364091-jabilplus-2_3-on-q3-beats-upside-revenue-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:41 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3364089\" data-ts=\"1529008796\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CNC\" target=\"_blank\">CNC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3364089-new-york-ag-on-board-centene-takeover-of-fidelis-care-shares-up-2-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">New York AG on board with Centene takeover of Fidelis Care; shares up 2% after hours</a></h4><ul><li>Centene (NYSE:<a href='https://seekingalpha.com/symbol/CNC' title='Centene Corporation'>CNC</a>) <a href=\"https://seekingalpha.com/pr/17192898-centene-receives-new-york-attorney-general-approval-fidelis-care-transaction\" target=\"_blank\">announces </a>that the New York Attorney General has signed off on its planned acquisition of New York Medicaid services provider Fidelis Care. The company expects the transaction to close by the end of the month.</li><li>Shares are up&nbsp;<font color='green'>2%</font>&nbsp;after hours.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3294993-centene-acquire-fidelis-care-3_75b-shares-1-percent-hours\" target=\"_blank\">Centene to acquire Fidelis Care for $3.75B; shares up 1% after hours</a> (Sept. 12, 2017)</li></ul><div class=\"tiny-share-widget\" data-id=\"3364089\" data-linked=\"New York AG on board with Centene takeover of Fidelis Care; shares up 2% after hours\" data-tweet=\"$CNC - New York AG on board with Centene takeover of Fidelis Care; shares up 2% after hours https://seekingalpha.com/news/3364089-new-york-ag-on-board-centene-takeover-of-fidelis-care-shares-up-2-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3364089-new-york-ag-on-board-centene-takeover-of-fidelis-care-shares-up-2-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:39 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3364072\" data-ts=\"1529007839\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ADBE\" target=\"_blank\">ADBE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3364072-adobe-systemsminus-3-despite-q2-beats-update\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Adobe Systems -3% despite Q2 beats (update)</a></h4><ul><li>Adobe Systems (NASDAQ:<a href='https://seekingalpha.com/symbol/ADBE' title='Adobe Systems Incorporated'>ADBE</a>)&nbsp;<font color='red'>drops 3%</font>&nbsp;aftermarket on Q2 results that beat EPS and revenue estimates with a 24% Y/Y revenue growth. Upside Q3 guidance from the conference call <a href=\"https://wwwimages2.adobe.com/content/dam/acom/en/investor-relations/pdfs/41608102/bB3oG2nBA0k7Ytfk.pdf\" target=\"_blank\">transcript</a> has revenue at $2.24B (consensus: $2.22B) and EPS at $1.68 (consensus: $1.64).</li><li>Key metrics: Digital Media revenue, $1.55B; Digital Media Annualized Recurring Revenue, $6.06B; Digital Experience revenue, $586M; cash flow from operations, $976M; deferred revenue, $2.63B; operating expenses, $1.22B; cash and equivalents, $2.99B.</li><li>Earnings call is scheduled for 5 PM Eastern with a webcast available <a href=\"https://www.adobe.com/investor-relations.html\" target=\"_blank\">here</a>.</li><li><a href=\"https://seekingalpha.com/pr/17192883-adobe-reports-record-revenue\" target=\"_blank\">Press release</a>.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3364049-adobe-systems-beats-0_12-beats-revenue\" target=\"_blank\">Adobe Systems beats by $0.12, beats on revenue</a> (June 14)</li></ul><div class=\"tiny-share-widget\" data-id=\"3364072\" data-linked=\"Adobe Systems -3% despite Q2 beats (update)\" data-tweet=\"$ADBE - Adobe Systems -3% despite Q2 beats (update) https://seekingalpha.com/news/3364072-adobe-systemsminus-3-despite-q2-beats-update?source=tweet\" data-url=\"https://seekingalpha.com/news/3364072-adobe-systemsminus-3-despite-q2-beats-update\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:23 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>20&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3364067\" data-ts=\"1529007693\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GNK\" target=\"_blank\">GNK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3364067-genco-shipping-launches-share-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Genco Shipping launches share offering</a></h4><ul>     <li>Genco Shipping (NYSE:<a href='https://seekingalpha.com/symbol/GNK' title='Genco Shipping & Trading Ltd.'>GNK</a>) <font color='red'>-5.9%</font> after-hours on news it has commenced a <a href=\"https://seekingalpha.com/pr/17192891-genco-shipping-and-trading-limited-announces-common-stock-offering\" target=\"_blank\">public offering</a> of common stock; no other details are provided related to the size of the offering.</li><li>GNK says it plans to use the proceeds for future vessel acquisitions.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3364067\" data-linked=\"Genco Shipping launches share offering\" data-tweet=\"$GNK - Genco Shipping launches share offering https://seekingalpha.com/news/3364067-genco-shipping-launches-share-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3364067-genco-shipping-launches-share-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:21 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>34&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3364054\" data-ts=\"1529007140\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IQ\" target=\"_blank\">IQ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3364054-iqiyi-appoints-ctrip-baidu-execs-to-board\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">IQiyi appoints Ctrip, Baidu execs to its board</a></h4><ul><li>        IQiyi (NASDAQ:<a href='https://seekingalpha.com/symbol/IQ' title='iQIYI, Inc'>IQ</a>) <a href=\"https://seekingalpha.com/pr/17191925-iqiyi-announces-changes-board-composition\" target=\"_blank\">announces</a> changes to its board Ctrip (NASDAQ:<a href='https://seekingalpha.com/symbol/CTRP' title='Ctrip.com International, Ltd.'>CTRP</a>) CEO Jane Jie Sun appointed as independent director.</li><li>                  Baidu (NASDAQ:<a href='https://seekingalpha.com/symbol/BIDU' title='Baidu, Inc.'>BIDU</a>) SVP Haifeng Wang was appointed as the board director.    </li><li>               IQiyi shares closed today&nbsp;<font color='green'>up 16.6%</font>&nbsp;to $40.51.</li></ul><div class=\"tiny-share-widget\" data-id=\"3364054\" data-linked=\"IQiyi appoints Ctrip, Baidu execs to its board\" data-tweet=\"$IQ $IQ $TCOM - IQiyi appoints Ctrip, Baidu execs to its board https://seekingalpha.com/news/3364054-iqiyi-appoints-ctrip-baidu-execs-to-board?source=tweet\" data-url=\"https://seekingalpha.com/news/3364054-iqiyi-appoints-ctrip-baidu-execs-to-board\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:12 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>121&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3364050\" data-ts=\"1529006900\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JBL\" target=\"_blank\">JBL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3364050-jabil-beats-0_01-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Jabil beats by $0.01, beats on revenue</a></h4><ul><li>Jabil (NYSE:<a href='https://seekingalpha.com/symbol/JBL' title='Jabil Inc.'>JBL</a>): Q3 EPS of $0.46 <font color='green'>beats by $0.01</font>.</li><li>Revenue of $5.44B (+21.2% Y/Y) <font color='green'>beats by $520M</font>.</li><li>Shares <font color='green'>+5.29%</font>.</li><li><a href='https://seekingalpha.com/pr/17192893-jabil-posts-third-quarter-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3364050\" data-linked=\"Jabil beats by $0.01, beats on revenue\" data-tweet=\"$JBL - Jabil beats by $0.01, beats on revenue https://seekingalpha.com/news/3364050-jabil-beats-0_01-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3364050-jabil-beats-0_01-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:08 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3364044\" data-ts=\"1529006543\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FNSR\" target=\"_blank\">FNSR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3364044-finisar-misses-0_07-revenue-in-line\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Finisar misses by $0.07,  revenue in-line</a></h4><ul><li>Finisar (NASDAQ:<a href='https://seekingalpha.com/symbol/FNSR' title='Finisar Corporation'>FNSR</a>): Q4 EPS of $0.05 <font color='red'>misses by $0.07</font>.</li><li>Revenue of $310.07M (-13.3% Y/Y) in-line.</li><li>Shares <font color='green'>+2%</font>.</li><li><a href='https://seekingalpha.com/pr/17192865-finisar-announces-fiscal-2018-financial-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3364044\" data-linked=\"Finisar misses by $0.07,  revenue in-line\" data-tweet=\"$FNSR - Finisar misses by $0.07, revenue in-line https://seekingalpha.com/news/3364044-finisar-misses-0_07-revenue-in-line?source=tweet\" data-url=\"https://seekingalpha.com/news/3364044-finisar-misses-0_07-revenue-in-line\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:02 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3364037\" data-ts=\"1529005570\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TNTR-OLD\" target=\"_blank\">TNTR-OLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3364037-tintriplus-37_8-on-high-volume\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tintri +37.8% on high volume</a></h4><ul><li>        Tintri (NASDAQ:<a href='https://seekingalpha.com/symbol/TNTR-OLD' title='Tintri, Inc.'>TNTR-OLD</a>)&nbsp;<font color='green'>gains 37.8%</font>&nbsp;to $0.73 on higher volume.</li><li>               Volume sits near 6.9M compared to the 1.18M three-month average.&nbsp;</li><li>               Tintri shares are&nbsp;<font color='green'>up 3.7%</font>&nbsp;in the past week,&nbsp;<font color='red'>down 49</font>% in the past month, and&nbsp;<font color='red'>down 89.6%</font>&nbsp;YTD. &nbsp;&nbsp; &nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3364037\" data-linked=\"Tintri +37.8% on high volume\" data-tweet=\"$TNTR-OLD - Tintri +37.8% on high volume https://seekingalpha.com/news/3364037-tintriplus-37_8-on-high-volume?source=tweet\" data-url=\"https://seekingalpha.com/news/3364037-tintriplus-37_8-on-high-volume\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:46 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3364036\" data-ts=\"1529004479\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FB\" target=\"_blank\">FB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3364036-facebooks-public-face-exits-role\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Facebook&#39;s public face exits role</a></h4><ul>   <li>Elliot Schrage -- Facebook's (<a href=\"http://seekingalpha.com/symbol/FB\" target=\"_blank\">FB</a> <font color='green'>+2.2%</font>) VP of communications and public policy -- is <a href=\"https://www.recode.net/2018/6/14/17462904/facebook-policy-comms-head-elliot-schrage-leaving\" target=\"_blank\">exiting the company</a>.</li>    <li>He's been with Facebook for a decade and has faced criticism lately amid a series of public controversies for the social networking giant.</li>    <li>&ldquo;Leading policy and communications for hyper growth technology companies is a joy &mdash; but it&rsquo;s also intense and leaves little room for much else,\" Schrage says. \"Mark (Zuckerberg), Sheryl (Sandberg) and I have been discussing this for a while.&ldquo;</li>    <li>Schrage had previously been VP of communications and public affairs for Google.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3364036\" data-linked=\"Facebook&#39;s public face exits role\" data-tweet=\"$FB - Facebook&#39;s public face exits role https://seekingalpha.com/news/3364036-facebooks-public-face-exits-role?source=tweet\" data-url=\"https://seekingalpha.com/news/3364036-facebooks-public-face-exits-role\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:27 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3364031\" data-ts=\"1529003243\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SPOT\" target=\"_blank\">SPOT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3364031-deutsche-bank-spotify-isnt-netflix-2_0\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Deutsche Bank: Spotify isn&#39;t &#39;Netflix 2.0&#39;</a></h4><ul>    <li>Deutsche Bank is struggling with the bull case on Spotify (NYSE:<a href='https://seekingalpha.com/symbol/SPOT' title='Spotify'>SPOT</a>) even as it stays positive on music companies overall.</li>    <li>\"We do not think Spotify is Netflix 2.0,\" says analyst Lloyd Walmsley, who's started coverage at Hold, pointing to a lack of visibility on its long-term margins and a lack of differentiated proprietary content. He'd prefer to invest on streaming tailwinds via major labels like Vivendi (<a href='https://seekingalpha.com/symbol/VIVHY' title='Vivendi SA ADR'>OTCPK:VIVHY</a>) instead. (h/t Bloomberg)</li>    <li>Walmsley has a price target of $155, implying 13.6% downside from the current $179.65.</li>    <li>Investors aren't nonplussed by the new rating, moving shares <font color='green'>up 5.2%</font> on the day to their new all-time high.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3364031\" data-linked=\"Deutsche Bank: Spotify isn&#39;t &#39;Netflix 2.0&#39;\" data-tweet=\"$SPOT $SPOT $VIVHY - Deutsche Bank: Spotify isn&#39;t &#39;Netflix 2.0&#39; https://seekingalpha.com/news/3364031-deutsche-bank-spotify-isnt-netflix-2_0?source=tweet\" data-url=\"https://seekingalpha.com/news/3364031-deutsche-bank-spotify-isnt-netflix-2_0\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:07 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3364026\" data-ts=\"1529002506\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AGMH\" target=\"_blank\">AGMH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3364026-technology-top-5-gainers-losers-of-2_55-pm-06-14-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top 5 Gainers / Losers as of 2.55 PM (06/14/2018)</a></h4><ul>     <li><strong>Gainers</strong>: <a href='https://seekingalpha.com/symbol/AGMH' title='AGM Group Holdings Inc.'>AGMH</a> <font color='green'>+66%</font>. <a href='https://seekingalpha.com/symbol/DBX' title='Dropbox'>DBX</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/IQ' title='iQIYI, Inc'>IQ</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/VSLR' title='Vivint Solar'>VSLR</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/CLPS' title='CLPS, Inc'>CLPS</a> <font color='green'>+11%</font>.</li>      <li><strong>Losers:</strong> <a href='https://seekingalpha.com/symbol/CLRO' title='ClearOne, Inc.'>CLRO</a> <font color='red'>-21%</font>. <a href='https://seekingalpha.com/symbol/BITA' title='Bitauto Holdings Limited'>BITA</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/NNDM' title='Nano Dimension Ltd ADR'>NNDM</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/MARK' title='Remark Holdings, Inc.'>MARK</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/ZDGE' title='Zedge, Inc.'>ZDGE</a> <font color='red'>-8%</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3364026\" data-linked=\"Technology - Top 5 Gainers / Losers as of 2.55 PM (06/14/2018)\" data-tweet=\"$AGMH $AGMH $DBX - Technology - Top 5 Gainers / Losers as of 2.55 PM (06/14/2018) https://seekingalpha.com/news/3364026-technology-top-5-gainers-losers-of-2_55-pm-06-14-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3364026-technology-top-5-gainers-losers-of-2_55-pm-06-14-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:55 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3364024\" data-ts=\"1529001906\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VSLR\" target=\"_blank\">VSLR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3364024-vivint-solarplus-26-since-closing-811m-in-new-financing\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Vivint Solar +26% since closing $811M in new financing</a></h4><ul>     <li>Vivint Solar (<a href='https://seekingalpha.com/symbol/VSLR' title='Vivint Solar'>VSLR</a> <font color='green'>+12.4%</font>) continues to power higher, capping a 26% surge following Monday's news that it <a href=\"https://seekingalpha.com/pr/17188883-vivint-solar-closes-811-million-new-financing\" target=\"_blank\">closed $811M in new financing</a> through two separate transactions.</li>     <li>VSLR says the proceeds from the financings will be used to help repay existing debt facilities&nbsp; and for general corporate purposes.</li>     <li>VSLR says the transactions lower its blended total credit spreads by ~160 bps.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3364024\" data-linked=\"Vivint Solar +26% since closing $811M in new financing\" data-tweet=\"$VSLR - Vivint Solar +26% since closing $811M in new financing https://seekingalpha.com/news/3364024-vivint-solarplus-26-since-closing-811m-in-new-financing?source=tweet\" data-url=\"https://seekingalpha.com/news/3364024-vivint-solarplus-26-since-closing-811m-in-new-financing\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:45 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3364023\" data-ts=\"1529001612\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BLBD\" target=\"_blank\">BLBD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3364023-blue-bird-rallies-after-buyback-disclosure\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Blue Bird rallies after buyback disclosure</a></h4><ul> <li>Blue Bird (NASDAQ:<a href='https://seekingalpha.com/symbol/BLBD' title='Blue Bird Corporation'>BLBD</a>) is <font color='green'>up 8.92%</font> after the company's board approves a share buyback allowance of $25M.</li> <li>Shares of Blue Bird broke back over $20 for the first time since late May.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3363832-blue-bird-announces-authorization-25m-stock-repurchase-program\" target=\"_blank\">Blue Bird announces authorization of a $25M stock repurchase program</a> (June 14)</li>   </ul><div class=\"tiny-share-widget\" data-id=\"3364023\" data-linked=\"Blue Bird rallies after buyback disclosure\" data-tweet=\"$BLBD - Blue Bird rallies after buyback disclosure https://seekingalpha.com/news/3364023-blue-bird-rallies-after-buyback-disclosure?source=tweet\" data-url=\"https://seekingalpha.com/news/3364023-blue-bird-rallies-after-buyback-disclosure\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:40 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3364017\" data-ts=\"1528999674\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BLCM\" target=\"_blank\">BLCM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3364017-bellicum-pharma-continues-rally-up-6\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bellicum Pharma continues rally, up 6%</a></h4><ul><li>Bellicum Pharmaceuticals (<a href='https://seekingalpha.com/symbol/BLCM' title='Bellicum Pharmaceuticals'>BLCM</a> <font color='green'>+6.4%</font>) regains it upward momentum, albeit on below-average volume. Shares have rallied&nbsp;<font color='green'>50%</font>&nbsp;since early May.</li><li>On Saturday, June 16, there will be<a href=\"http://ir.bellicum.com/news-and-events/events-and-presentations\" target=\"_blank\"> two presentations</a> of BPX-501 data at the European Hematology Association Congress in Stockholm.</li></ul><div class=\"tiny-share-widget\" data-id=\"3364017\" data-linked=\"Bellicum Pharma continues rally, up 6%\" data-tweet=\"$BLCM - Bellicum Pharma continues rally, up 6% https://seekingalpha.com/news/3364017-bellicum-pharma-continues-rally-up-6?source=tweet\" data-url=\"https://seekingalpha.com/news/3364017-bellicum-pharma-continues-rally-up-6\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:07 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3364015\" data-ts=\"1528999309\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BOXL\" target=\"_blank\">BOXL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3364015-boxlight-set-to-join-russell-microcap-index\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Boxlight set to join Russell Microcap Index</a></h4><ul>     <li>Boxlight (<a href='https://seekingalpha.com/symbol/BOXL' title='Boxlight'>BOXL</a> <font color='green'>+4.2%</font>) is set to join the <a href=\"https://seekingalpha.com/pr/17192731-boxlight-set-join-russell-microcap-index\" target=\"_blank\">Russell Microcap Index</a> at the conclusion of the Russell U.S. Indexes annual reconstitution.</li>     <li>The move is effective after the market opens on June 25.</li>     <li>\"We are honored to be added to the Russell Microcap Index to raise Boxlight&rsquo;s visibility and public awareness within the investment community,\" said Michael Pope, President of Boxlight.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3364015\" data-linked=\"Boxlight set to join Russell Microcap Index\" data-tweet=\"$BOXL - Boxlight set to join Russell Microcap Index https://seekingalpha.com/news/3364015-boxlight-set-to-join-russell-microcap-index?source=tweet\" data-url=\"https://seekingalpha.com/news/3364015-boxlight-set-to-join-russell-microcap-index\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3364014\" data-ts=\"1528999288\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EGY\" target=\"_blank\">EGY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3364014-energy-materials-top-5-gainers-losers-of-2-00-pm-06-14-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top 5 Gainers / Losers as of 2:00 PM (06/14/2018)</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/EGY' title='VAALCO Energy, Inc.'>EGY</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/ZKIN' title='ZK International Group Co., Ltd.'>ZKIN</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/AUG' title='Auryn Resources Inc.'>AUG</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/EMX' title='EMX Royalty Corporation'>EMX</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/MBII' title='Marrone Bio Innovations, Inc.'>MBII</a> <font color='green'>+6%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/GEVO' title='Gevo, Inc.'>GEVO</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/LGCYO' title='Legacy Reserves LP Cum Red Perp Pfd Units Series B'>LGCYO</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/TAT' title='TransAtlantic Petroleum Ltd.'>TAT</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/ZN' title='Zion Oil & Gas Inc'>ZN</a> <font color='red'>-5%</font>. <a href='https://seekingalpha.com/symbol/EGC' title='Energy XXI Gulf Coast, Inc.'>EGC</a> <font color='red'>-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3364014\" data-linked=\"Energy/Materials - Top 5 Gainers / Losers as of 2:00 PM (06/14/2018)\" data-tweet=\"$EGY $EGY $ZKIN - Energy/Materials - Top 5 Gainers / Losers as of 2:00 PM (06/14/2018) https://seekingalpha.com/news/3364014-energy-materials-top-5-gainers-losers-of-2-00-pm-06-14-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3364014-energy-materials-top-5-gainers-losers-of-2-00-pm-06-14-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:01 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3364011\" data-ts=\"1528998683\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DISCA\" target=\"_blank\">DISCA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3364011-discovery-announces-new-manhattan-hq\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Discovery announces new Manhattan HQ</a></h4><ul>   <li>Discovery (<a href=\"http://seekingalpha.com/symbol/DISCA\" target=\"_blank\">DISCA</a> <font color='green'>+3.6%</font>) has officially selected a new Flatiron district building in Manhattan as its new global headquarters.</li>    <li>The company will consolidate locations at 230 Park Ave. South, planning to start moving in fall 2019 after a series of renovations, and continuing through mid-2020.</li>    <li>The building has about 250,000 square feet; Discovery had been leasing about 160,000 square feet in Manhattan.</li>    <li>In January, the company said it planned to relocate headquarters from Silver Spring, Md. (where it owns a 550,000-square-foot building) to New York City. And in March, reports surprisingly showed Discovery <a href=\"https://seekingalpha.com/news/3338445-discovery-upgrade-target-raise-considers-new-hq\" target=\"_blank\">leaning toward the Flatiron district building</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3364011\" data-linked=\"Discovery announces new Manhattan HQ\" data-tweet=\"$DISCA $DISCB $DISCK - Discovery announces new Manhattan HQ https://seekingalpha.com/news/3364011-discovery-announces-new-manhattan-hq?source=tweet\" data-url=\"https://seekingalpha.com/news/3364011-discovery-announces-new-manhattan-hq\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:51 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3364125\" data-ts=\"1528995945\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BRFS\" target=\"_blank\">BRFS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3364125-former-petrobras-ceo-parente-take-helm-brazils-brf\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Former Petrobras CEO Parente could take helm at Brazil&#39;s BRF</a></h4><ul>     <li>Brazilian food processor BRF (<a href='https://seekingalpha.com/symbol/BRFS' title='BRF-Brasil Foods S.A.'>BRFS</a> <font color='green'>+4.2%</font>) shoots higher after former Petrobras CEO Pedro Parente reportedly is <a href=\"https://www.reuters.com/article/us-brf-ceo/former-petrobras-ceo-parente-invited-to-lead-brazils-brf-source-idUSKBN1J93A5\" target=\"_blank\">asked to run the company</a>.</li>     <li>Parente already is BRF's chairman, a post he took in April when BRF shareholders sought a management overhaul in the wake of a food safety probe that caused plant closures.</li>     <li>Parente has a six-month non-compete agreement from Petrobras, Reuters reports, and would need clearance from a government commission to be able to take on the BRF job while in effect.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3364125\" data-linked=\"Former Petrobras CEO Parente could take helm at Brazil&#39;s BRF\" data-tweet=\"$BRFS - Former Petrobras CEO Parente could take helm at Brazil&#39;s BRF https://seekingalpha.com/news/3364125-former-petrobras-ceo-parente-take-helm-brazils-brf?source=tweet\" data-url=\"https://seekingalpha.com/news/3364125-former-petrobras-ceo-parente-take-helm-brazils-brf\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:05 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3364000\" data-ts=\"1528995650\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TCI\" target=\"_blank\">TCI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3364000-financials-top-gainers-losers-of-1-00-pm-06-14-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials - Top Gainers / Losers as of 1:00 PM (06/14/2018)</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/TCI' title='Transcontinental Realty Investors Inc.'>TCI</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/FANH' title='Fanhua Inc.'>FANH</a> <font color='green'>+10%.</font></li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/BMA' title='Banco Macro S.A.'>BMA</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/SUPV' title='Grupo Supervielle'>SUPV</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/OXBR' title='Oxbridge Re Holdings Limited'>OXBR</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/GGAL' title='Grupo Financiero Galicia S.A.'>GGAL</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/LOOP' title='Loop Industries, Inc.'>LOOP</a> <font color='red'>-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3364000\" data-linked=\"Financials - Top Gainers / Losers as of 1:00 PM (06/14/2018)\" data-tweet=\"$TCI $TCI $FANH - Financials - Top Gainers / Losers as of 1:00 PM (06/14/2018) https://seekingalpha.com/news/3364000-financials-top-gainers-losers-of-1-00-pm-06-14-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3364000-financials-top-gainers-losers-of-1-00-pm-06-14-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3363998\" data-ts=\"1528995031\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NTDOY\" target=\"_blank\">NTDOY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3363998-nintendo-slipping-after-e3-lineup\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nintendo slipping further after E3 lineup</a></h4><ul>   <li>Nintendo (<a href=\"http://seekingalpha.com/symbol/NTDOY\" target=\"_blank\">NTDOY</a> <font color='red'>-3.5%</font>) is on its second day sharply lower -- and heading for its worst month as a stock in years -- after an E3 presentation that has come off as a dud.</li>    <li>Reggie Fils-Aime, head of the company's U.S. operations, says <a href=\"https://www.bloomberg.com/news/articles/2018-06-14/nintendo-s-fils-aime-hits-back-at-analysts-as-stock-declines\" target=\"_blank\">analysts are wrong</a> in sentiment that the company is out of surprises, and says aside from what it announced at E3, there's more to come \"in the weeks and months ahead.\"</li>    <li>Analysts like Ace Research's Hideki Yasuda criticized the game lineup Nintendo unveiled as weak on third-party publisher content: \"Something was lacking.\" And the company's planned December release of <i>Super Smash Bros. Ultimate</i> is coming later than expected.</li>    <li>Even so, Yasuda says the company's internal content (including Super Mario Party and new Pokemon) should create solid sales momentum.</li>    <li>&ldquo;As you look at Nintendo over these many years, if you look at the number of analysts who have actually gotten it right, it&rsquo;s fairly small,\" Fils-Aime told Bloomberg. \"And it&rsquo;s because we as a company, we hold things close to the vest. We love to surprise the overall community and environment, and when we surprise, we surprise big.&rdquo;</li>    <li>Shares are now <font color='red'>down 9.1%</font> in U.S. trading over a two-day span.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3363998\" data-linked=\"Nintendo slipping further after E3 lineup\" data-tweet=\"$NTDOY - Nintendo slipping further after E3 lineup https://seekingalpha.com/news/3363998-nintendo-slipping-after-e3-lineup?source=tweet\" data-url=\"https://seekingalpha.com/news/3363998-nintendo-slipping-after-e3-lineup\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:50 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3363997\" data-ts=\"1528994999\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AGMH\" target=\"_blank\">AGMH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3363997-midday-gainers-losers-06-14-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers (06/14/2018)</a></h4><ul>     <li><strong>Gainers:&nbsp;</strong><a href='https://seekingalpha.com/symbol/AGMH' title='AGM Group Holdings Inc.'>AGMH</a> <font color='green'>+79%</font>. <a href='https://seekingalpha.com/symbol/FLKS' title='Flex Pharma'>FLKS</a> <font color='green'>+48%</font>. <a href='https://seekingalpha.com/symbol/ETSY' title='Etsy, Inc.'>ETSY</a> <font color='green'>+30%</font>. <a href='https://seekingalpha.com/symbol/DEST' title='Destination Maternity Corporation'>DEST</a> <font color='green'>+27%</font>. <a href='https://seekingalpha.com/symbol/THST' title='Truett-Hurst, Inc.'>THST</a> <font color='green'>+26%</font>. <a href='https://seekingalpha.com/symbol/NITE' title='Nightstar Therapeutics plc'>NITE</a> <font color='green'>+20%</font>. <a href='https://seekingalpha.com/symbol/DBX' title='Dropbox'>DBX</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/INSY' title='Insys Therapeutics, Inc.'>INSY</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/CLPS' title='CLPS, Inc'>CLPS</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/LIVX' title='LiveXLive Media, Inc.'>LIVX</a> <font color='green'>+13%</font>.</li>     <li><strong>Losers:&nbsp;</strong><a href='https://seekingalpha.com/symbol/TLRD' title='Tailored Brands, Inc'>TLRD</a> <font color='red'>-22%</font>. <a href='https://seekingalpha.com/symbol/SNOA' title='Sonoma Pharmaceuticals, Inc.'>SNOA</a> <font color='red'>-21%</font>. <a href='https://seekingalpha.com/symbol/ACHV' title='Achieve Life Sciences, Inc.'>ACHV</a> <font color='red'>-19%</font>. <a href='https://seekingalpha.com/symbol/CLRO' title='ClearOne, Inc.'>CLRO</a> <font color='red'>-18%</font>. <a href='https://seekingalpha.com/symbol/MIK' title='The Michaels Companies'>MIK</a> <font color='red'>-18%</font>. <a href='https://seekingalpha.com/symbol/CULP' title='Culp, Inc.'>CULP</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/BMA' title='Banco Macro S.A.'>BMA</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/MKGI' title='Monaker Group, Inc.'>MKGI</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/BITA' title='Bitauto Holdings Limited'>BITA</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/NNDM' title='Nano Dimension Ltd ADR'>NNDM</a> <font color='red'>-11%</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3363997\" data-linked=\"Midday Gainers / Losers (06/14/2018)\" data-tweet=\"$AGMH $AGMH $SLRX - Midday Gainers / Losers (06/14/2018) https://seekingalpha.com/news/3363997-midday-gainers-losers-06-14-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3363997-midday-gainers-losers-06-14-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:49 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3363996\" data-ts=\"1528994673\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TCI\" target=\"_blank\">TCI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3363996-transcontinental-realty-investors-announces-strategic-initiatives-shares-jumps-11\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Transcontinental Realty Investors announces strategic initiatives; Shares jumps 11%</a></h4><ul>     <li>Transcontinental Realty Investors (<a href='https://seekingalpha.com/symbol/TCI' title='Transcontinental Realty Investors Inc.'>TCI</a> <font color='green'>+10.9%</font>) has entered into a Joint Venture with a major NYSE financial institution. This joint venture agreement conveys existing multifamily assets as well as projects under development to a newly-formed entity called Victory Abode Apartments, LLC.</li>     <li>The assets involved include 41 existing properties and 12 properties under development encompassing 8,082 apartment units, with the rights to jointly develop 23 additional projects.</li>     <li>The company's second major strategic transaction of the year is the planned sale of its 4 commercial office buildings to a private company with significant real estate holdings.</li>     <li>The sale of these commercial assets is tied to the NOI calculation at the end of the ~45 day due diligence period. TCI is confident that the asset values will remain attractive to all parties.</li><li><a href=\"https://seekingalpha.com/pr/17192610-transcontinental-realty-investors-inc-announces-two-major-strategic-initiatives\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3363996\" data-linked=\"Transcontinental Realty Investors announces strategic initiatives; Shares jumps 11%\" data-tweet=\"$TCI - Transcontinental Realty Investors announces strategic initiatives; Shares jumps 11% https://seekingalpha.com/news/3363996-transcontinental-realty-investors-announces-strategic-initiatives-shares-jumps-11?source=tweet\" data-url=\"https://seekingalpha.com/news/3363996-transcontinental-realty-investors-announces-strategic-initiatives-shares-jumps-11\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:44 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3363995\" data-ts=\"1528994573\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DBX\" target=\"_blank\">DBX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3363995-dropboxplus-19_4-on-high-volume\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dropbox +19.4% on high volume</a></h4><ul><li>        Dropbox (NASDAQ:<a href='https://seekingalpha.com/symbol/DBX' title='Dropbox'>DBX</a>)&nbsp;<font color='green'>gains 19.4%</font>&nbsp;towards an all-time high on higher volume of roughly 12.7M compared to the 4.12M average volume.</li><li>               Dropbox shares are&nbsp;<font color='green'>up 1.4%</font>&nbsp;in the past week,&nbsp;<font color='green'>5.7%</font>&nbsp;in the past month, and&nbsp;<font color='green'>11.2%</font>&nbsp;YTD since the March IPO. &nbsp;&nbsp; &nbsp;&nbsp;&nbsp;</li><li>Competitor Box (NYSE:<a href='https://seekingalpha.com/symbol/BOX' title='Box'>BOX</a>) is also getting a boost with shares up 3.4% to $27.02.</li></ul><div class=\"tiny-share-widget\" data-id=\"3363995\" data-linked=\"Dropbox +19.4% on high volume\" data-tweet=\"$DBX $DBX $BOX - Dropbox +19.4% on high volume https://seekingalpha.com/news/3363995-dropboxplus-19_4-on-high-volume?source=tweet\" data-url=\"https://seekingalpha.com/news/3363995-dropboxplus-19_4-on-high-volume\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:42 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>21&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3363994\" data-ts=\"1528994333\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CHTR\" target=\"_blank\">CHTR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3363994-gci-liberty-prices-debenture-offering-glibaplus-3-chtrplus-3_5\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GCI Liberty prices debenture offering; GLIBA +3, CHTR +3.5%</a></h4><ul>   <li>GCI Liberty (<a href=\"http://seekingalpha.com/symbol/GLIBA\" target=\"_blank\">GLIBA</a> <font color='green'>+3%</font>) has priced its private offering of $415M in 1.75% exchangeable senior debentures due 2046.</li>    <li>Purchasers have an option to buy additional debentures up to an aggregate $62.25M.</li>    <li>When debentures are exchanged, GCI Liberty has the option of delivering Charter (NASDAQ:<a href='https://seekingalpha.com/symbol/CHTR' title='Charter Communications, Inc.'>CHTR</a>) Class A common stock, cash, or a combination of those.</li>    <li>Initially, 2.6989 shares of Charter Class A common stock is attributable to each $1,000 in debentures (initial exchange price of $370.52 per share).</li>    <li>Charter shares are <font color='green'>up 3.5%</font> today to $295.07.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3363994\" data-linked=\"GCI Liberty prices debenture offering; GLIBA +3, CHTR +3.5%\" data-tweet=\"$CHTR $CHTR $GLIBA - GCI Liberty prices debenture offering; GLIBA +3, CHTR +3.5% https://seekingalpha.com/news/3363994-gci-liberty-prices-debenture-offering-glibaplus-3-chtrplus-3_5?source=tweet\" data-url=\"https://seekingalpha.com/news/3363994-gci-liberty-prices-debenture-offering-glibaplus-3-chtrplus-3_5\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:38 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3363986\" data-ts=\"1528994064\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CULP\" target=\"_blank\">CULP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3363986-culp-down-14-on-q4-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Culp down 14% on Q4 results</a></h4><ul><li>Culp (<a href='https://seekingalpha.com/symbol/CULP' title='Culp, Inc.'>CULP</a> <font color='red'>-14%</font>) reported Q4 net sales of $78.2M (+1.1% Y/Y). Segment sales: Mattress fabric $46.5M (-4.7% Y/Y) and upholstery fabric $31.7M (+11% Y/Y).</li><li>Q4 Overall operating margin&nbsp;<font color='red'>declined by 100 bps</font>&nbsp;to 8.3%. Segment operating margins: Mattress fabric&nbsp;<font color='red'>declined by 150 bps&nbsp;</font>to 13.1% and upholstery fabric&nbsp;<font color='red'>declined by 200 bps</font>&nbsp;to 13.4%.</li><li>Q4 Adj. EBITDA margin&nbsp;<font color='red'>declined by 170 bps</font>&nbsp;to 10.51%.</li><li>Cash flow from operations $27.5M, down by 24.6% Y/Y.</li><li>Culp announced acquisition of eLuxury, an internet company offering bedding accessories and home goods direct to consumers. The acquisition will help Culp expand addressable market and add a new sales channel. eLuxury&rsquo;s revenue is on a current annual run rate of $22M for 2018.</li><li>&ldquo;As we look ahead to fiscal 2019, we are facing a significant challenge with the growth in imported Chinese mattresses and its effect on fabric demand from many of our customers. We are aware of actions being considered by the industry to address this situation in the near term, and we are optimistic that such actions will be successful&rdquo;, said Frank Saxon, President and CEO.</li><li><strong>1Q19 Outlook:</strong> Sales to be down ~10% Y/Y; pre-tax income $3.8-4.8M and Capex $6-7M.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3363765-culp-misses-0_06-misses-revenue\" target=\"_blank\">Culp misses by $0.06, misses on revenue</a> (June 13)</li><li><a href=\"https://seekingalpha.com/article/4181673-culp-inc-2018-q4-results-earnings-call-slides\" target=\"_blank\">Slides</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3363986\" data-linked=\"Culp down 14% on Q4 results\" data-tweet=\"$CULP - Culp down 14% on Q4 results https://seekingalpha.com/news/3363986-culp-down-14-on-q4-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3363986-culp-down-14-on-q4-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:34 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3363988\" data-ts=\"1528993465\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OPGN\" target=\"_blank\">OPGN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3363988-opgen-continues-selloff-down-8\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">OpGen continues selloff, down 8%</a></h4><ul><li>Nano cap OpGen (<a href='https://seekingalpha.com/symbol/OPGN' title='OpGen'>OPGN</a> <font color='red'>-7.8%</font>) is down on below-average volume. Shares have retreated&nbsp;<font color='red'>27%</font>&nbsp;since touching $2.90 on Tuesday.</li><li>This morning, the company <a href=\"https://seekingalpha.com/pr/17192151-opgen-modifies-terms-debt-merck-global-health-innovation-fund\" target=\"_blank\">announced </a>that it will issue shares of stock to pay accrued interest related to its $1M promissory note with Merck Global Innovation Fund, LLC. Under the terms of the amendment, which also extends the maturity date to July 1, 2021, it will issue shares to Merck Global to pay $285.5K in accrued interest as of July 14 in a private transaction. The interest rate of the note remains 10%.</li></ul><div class=\"tiny-share-widget\" data-id=\"3363988\" data-linked=\"OpGen continues selloff, down 8%\" data-tweet=\"$OPGN - OpGen continues selloff, down 8% https://seekingalpha.com/news/3363988-opgen-continues-selloff-down-8?source=tweet\" data-url=\"https://seekingalpha.com/news/3363988-opgen-continues-selloff-down-8\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:24 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3363990\" data-ts=\"1528993191\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FOX\" target=\"_blank\">FOX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3363990-rbc-comcast-may-need-to-raise-sky-bid\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">RBC: Comcast may need to raise Sky bid</a></h4><ul>   <li>With Comcast's (<a href=\"http://seekingalpha.com/symbol/CMCSA\" target=\"_blank\">CMCSA</a> <font color='green'>+3.3%</font>) <a href=\"https://seekingalpha.com/news/3363754-comcast-unveils-65b-cash-bid-fox-assets-setting-disney-war\" target=\"_blank\">formal offer for Fox</a> (<a href='https://seekingalpha.com/symbol/FOX' title='Twenty-First Century Fox, Inc.'>FOX</a> <font color='green'>+1.8%</font>, <a href='https://seekingalpha.com/symbol/FOXA' title='Twenty-First Century Fox, Inc.'>FOXA</a> <font color='green'>+2%</font>) on the books, RBC has turned to the UK takeover code to figure that could mean a higher bid for Sky (<a href=\"http://seekingalpha.com/symbol/SKYAY\" target=\"_blank\">SKYAY</a> <font color='green'>+0.6%</font>).</li>    <li>A strict interpretation of rule 9.1 (the chain principle) leads RBC to calculate that the premium that Comcast is paying over Disney's offer comes to about &pound;13.18/share for Sky, Bloomberg reports. A mandatory offer under the rule from Comcast or Fox wouldn't need to be raised in the case that Disney or Comcast increased their offer for Fox.</li>    <li>Sky shares closed <font color='green'>up 1%</font> in London to &pound;13.4832.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3363990\" data-linked=\"RBC: Comcast may need to raise Sky bid\" data-tweet=\"$FOX $FOX $FOXA - RBC: Comcast may need to raise Sky bid https://seekingalpha.com/news/3363990-rbc-comcast-may-need-to-raise-sky-bid?source=tweet\" data-url=\"https://seekingalpha.com/news/3363990-rbc-comcast-may-need-to-raise-sky-bid\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:19 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3363985\" data-ts=\"1528992862\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MD\" target=\"_blank\">MD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3363985-mednax-slips-5-insiders-sell-shares\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MEDNAX slips 5% as insiders sell shares</a></h4><ul><li>MEDNAX (<a href='https://seekingalpha.com/symbol/MD' title='Mednax, Inc.'>MD</a> <font color='red'>-4.7%</font>) is down on average volume. After the close yesterday, three executive filed notices of stock sales.</li><li>Principal Accounting Officer John Pepia: <a href=\"https://www.sec.gov/Archives/edgar/data/893949/000120919118037509/xslF345X03/doc4.xml\" target=\"_blank\">6,516 shares</a>.</li><li>Chief Financial Officer Vivian Lopez-Blanco: <a href=\"https://www.sec.gov/Archives/edgar/data/893949/000120919118037504/xslF345X03/doc4.xml\" target=\"_blank\">13,942 shares</a>.</li><li>SVP, General Counsel and Secretary Dominic Andreano: <a href=\"https://www.sec.gov/Archives/edgar/data/893949/000120919118037500/xslF345X03/doc4.xml\" target=\"_blank\">18,000 shares</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3363985\" data-linked=\"MEDNAX slips 5% as insiders sell shares\" data-tweet=\"$MD - MEDNAX slips 5% as insiders sell shares https://seekingalpha.com/news/3363985-mednax-slips-5-insiders-sell-shares?source=tweet\" data-url=\"https://seekingalpha.com/news/3363985-mednax-slips-5-insiders-sell-shares\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:14 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3363984\" data-ts=\"1528992086\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BRFS\" target=\"_blank\">BRFS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3363984-consumer-top-gainers-losers-of-12-00-pm-06-14-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 PM (06/14/2018)</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/BRFS' title='BRF-Brasil Foods S.A.'>BRFS</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/AVP' title='Avon Products, Inc.'>AVP</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/BLBD' title='Blue Bird Corporation'>BLBD</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/NTZ' title='Natuzzi S.p.A.'>NTZ</a> <font color='green'>+6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3363984\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 PM (06/14/2018)\" data-tweet=\"$BRFS $BRFS $AVP - Consumer - Top Gainers / Losers as of 12:00 PM (06/14/2018) https://seekingalpha.com/news/3363984-consumer-top-gainers-losers-of-12-00-pm-06-14-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3363984-consumer-top-gainers-losers-of-12-00-pm-06-14-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3363983\" data-ts=\"1528991923\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KTWO\" target=\"_blank\">KTWO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3363983-k2m-group-prices-convertible-debt-offering-shares-down-7\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">K2M Group prices convertible debt offering; shares down 7%</a></h4><ul><li>Thinly traded K2M Group Holdings (<a href='https://seekingalpha.com/symbol/KTWO' title='K2M Group Holdings, Inc.'>KTWO</a> <font color='red'>-6.5%</font>) is down on more than a 4x surge in volume in reaction to its <a href=\"https://seekingalpha.com/pr/17192089-k2m-group-holdings-inc-announces-pricing-private-offering-65_0-million-aggregate-principal\" target=\"_blank\">private offering</a> of 3.00% Convertible Senior Notes due 2025 to institutional investors.</li><li>The initial conversion rate is 35.2930 common shares per $1,000 principal amount of the Notes ($28.33/share).</li><li>Net proceeds of almost $62M will be used to repay ~$18M in borrowings under its credit revolver and for general corporate purposes.</li></ul><div class=\"tiny-share-widget\" data-id=\"3363983\" data-linked=\"K2M Group prices convertible debt offering; shares down 7%\" data-tweet=\"$KTWO - K2M Group prices convertible debt offering; shares down 7% https://seekingalpha.com/news/3363983-k2m-group-prices-convertible-debt-offering-shares-down-7?source=tweet\" data-url=\"https://seekingalpha.com/news/3363983-k2m-group-prices-convertible-debt-offering-shares-down-7\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:58 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3363979\" data-ts=\"1528990743\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/INSY\" target=\"_blank\">INSY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3363979-insys-epinephrine-nasal-spray-shows-encouraging-action-in-early-stage-study-shares-ahead-13\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">INSYS&#39; epinephrine nasal spray shows encouraging action in early-stage study; shares ahead 13%</a></h4><ul><li>INSYS Therapeutics (<a href='https://seekingalpha.com/symbol/INSY' title='Insys Therapeutics, Inc.'>INSY</a> <font color='green'>+12.5%</font>) is up on double normal volume in apparent response to its <a href=\"https://seekingalpha.com/pr/17192107-epinephrine-nasal-spray-development-treatment-anaphylaxis-shows-promise-potential-alternative\" target=\"_blank\">announcement </a>of positive data from an early-stage trial assessing its epinephrine nasal spray for the treatment of acute allergic reaction (anaphylaxis).</li><li>Results from a pharmacokinetics study in 60 people with seasonal allergies showed that the bioavailability of nasally administered epinephrine was similar to Mylan's (<a href='https://seekingalpha.com/symbol/MYL' title='Mylan Inc'>MYL</a> <font color='red'>-5.2%</font>) EpiPen administered via intramuscular injection. Rapid drug absorption was also observed.</li><li>The company says it plans to work with the FDA to determine the best path to making the product available to consumers considering the current shortage of epinephrine.</li><li>Related ticker: (<a href='https://seekingalpha.com/symbol/ADMP' title='Adamis Pharmaceuticals Corp.'>ADMP</a> <font color='green'>+0.3%</font>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3363979\" data-linked=\"INSYS&#39; epinephrine nasal spray shows encouraging action in early-stage study; shares ahead 13%\" data-tweet=\"$INSY $INSYQ $MYL - INSYS&#39; epinephrine nasal spray shows encouraging action in early-stage study; shares ahead 13% https://seekingalpha.com/news/3363979-insys-epinephrine-nasal-spray-shows-encouraging-action-in-early-stage-study-shares-ahead-13?source=tweet\" data-url=\"https://seekingalpha.com/news/3363979-insys-epinephrine-nasal-spray-shows-encouraging-action-in-early-stage-study-shares-ahead-13\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:39 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3363977\" data-ts=\"1528990583\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WIT\" target=\"_blank\">WIT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3363977-wipro-announces-deal-nokia-witminus-2_8\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Wipro announces deal with Nokia; WIT -2.8%</a></h4><ul><li>        Wipro (NYSE:<a href='https://seekingalpha.com/symbol/WIT' title='Wipro Limited'>WIT</a>) <a href=\"https://www.businesswire.com/news/home/20180614005686/en/Nokia-Selects-Wipro-Accelerate-Supply-Chain-Digital\" target=\"_blank\">announces</a> a multi-year business process services deal with Nokia (NYSE:<a href='https://seekingalpha.com/symbol/NOK' title='Nokia Corporation'>NOK</a>). &nbsp;</li><li>        Wipro will design and digitize Nokia&rsquo;s sales order operations.</li><li>               Wipro shares are&nbsp;<font color='red'>down 2.8%</font>&nbsp;to $4.76.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3363977\" data-linked=\"Wipro announces deal with Nokia; WIT -2.8%\" data-tweet=\"$WIT $WIT $NOK - Wipro announces deal with Nokia; WIT -2.8% https://seekingalpha.com/news/3363977-wipro-announces-deal-nokia-witminus-2_8?source=tweet\" data-url=\"https://seekingalpha.com/news/3363977-wipro-announces-deal-nokia-witminus-2_8\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:36 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3363973\" data-ts=\"1528989819\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AFMD\" target=\"_blank\">AFMD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3363973-affimed-up-11\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Affimed up 11%</a></h4><ul><li>Thinly traded micro cap Affimed Therapeutics (<a href='https://seekingalpha.com/symbol/AFMD' title='Affimed Therapeutics'>AFMD</a> <font color='green'>+11.1%</font>) is up more than a 5x surge in volume. Shares have doubled this year.</li><li>No particular news accounts for today's action. At the end of December 2017, it had $35.4M in cash and equivalents and operations consumed $25.5M during the year. In February, it filed a <a href=\"https://www.sec.gov/Archives/edgar/data/1608390/000095010318002059/dp85754_424b5.htm\" target=\"_blank\">prospectus supplement</a> for a public offering of 11.5M shares.</li><li><strong>Update</strong>: The company will host a conference call tomorrow, June 15, at 8:30 am ET to update investors on its Phase 1b clinical trial evaluating AFM13 + Merck's Keytruda (pembrolizumab) in lymphoma patients. Preliminary data announced in February showed an 89% response rate with an implied disease control rate of 100% (nine patients).</li><li>Previously: <a href=\"https://seekingalpha.com/news/3327375-updated-data-affimeds-afm13-shows-89-percent-response-rate-hl-patients-shares-28-percent\" target=\"_blank\">Updated data on Affimed's AFM13 shows 89% response rate in HL patients; shares up 28%</a> (Feb. 1)</li></ul><div class=\"tiny-share-widget\" data-id=\"3363973\" data-linked=\"Affimed up 11%\" data-tweet=\"$AFMD - Affimed up 11% https://seekingalpha.com/news/3363973-affimed-up-11?source=tweet\" data-url=\"https://seekingalpha.com/news/3363973-affimed-up-11\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:23 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3363969\" data-ts=\"1528988801\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FLKS\" target=\"_blank\">FLKS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3363969-flex-pharma-bargain-hunters-move-in-shares-up-44\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Flex Pharma bargain hunters move in, shares up 44%</a></h4><ul><li>Thinly traded nano cap Flex Pharma (<a href='https://seekingalpha.com/symbol/FLKS' title='Flex Pharma'>FLKS</a> <font color='green'>+44.2%</font>) is up on a whopping 56x surge in volume as bargain hunters rush in. Shares cratered&nbsp;<font color='red'>75%</font>&nbsp;yesterday after the company announced that it was terminating mid-stage development of lead candidate FLX-787 in ALS and CMT.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3363567-flex-pharma-bails-development-lead-candidate-als-cmt-shares-61-percent-premarket\" target=\"_blank\">Flex Pharma bails on development of lead candidate in ALS and CMT; shares down 61% premarket</a> (June 13)</li></ul><div class=\"tiny-share-widget\" data-id=\"3363969\" data-linked=\"Flex Pharma bargain hunters move in, shares up 44%\" data-tweet=\"$FLKS $SLRX - Flex Pharma bargain hunters move in, shares up 44% https://seekingalpha.com/news/3363969-flex-pharma-bargain-hunters-move-in-shares-up-44?source=tweet\" data-url=\"https://seekingalpha.com/news/3363969-flex-pharma-bargain-hunters-move-in-shares-up-44\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:06 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3363965\" data-ts=\"1528988435\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FLKS\" target=\"_blank\">FLKS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3363965-healthcare-top-5-gainers-losers-of-11-00-06-14-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:00 AM (06/14/2018)</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/FLKS' title='Flex Pharma'>FLKS</a> <font color='green'>+37%</font>. <a href='https://seekingalpha.com/symbol/NITE' title='Nightstar Therapeutics plc'>NITE</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/AFMD' title='Affimed Therapeutics'>AFMD</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/INSY' title='Insys Therapeutics, Inc.'>INSY</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/TLGT' title='Teligent, Inc.'>TLGT</a> <font color='green'>+9%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/SNOA' title='Sonoma Pharmaceuticals, Inc.'>SNOA</a> <font color='red'>-22%</font>. <a href='https://seekingalpha.com/symbol/ACHV' title='Achieve Life Sciences, Inc.'>ACHV</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/KTWO' title='K2M Group Holdings, Inc.'>KTWO</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/OPGN' title='OpGen'>OPGN</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/MD' title='Mednax, Inc.'>MD</a> <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3363965\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:00 AM (06/14/2018)\" data-tweet=\"$FLKS $SLRX $NITE - Healthcare - Top 5 Gainers / Losers as of 11:00 AM (06/14/2018) https://seekingalpha.com/news/3363965-healthcare-top-5-gainers-losers-of-11-00-06-14-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3363965-healthcare-top-5-gainers-losers-of-11-00-06-14-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:00 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3363959\" data-ts=\"1528987643\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RNET\" target=\"_blank\">RNET</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3363959-rignetplus-2_4-maxim-gives-buy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">RigNet +2.4% as Maxim gives it a Buy</a></h4><ul>   <li>RigNet (NASDAQ:<a href='https://seekingalpha.com/symbol/RNET' title='RigNet'>RNET</a>) is <font color='green'>up 2.4%</font> after an initiation by Maxim at Buy, what looks to be the company's first Buy recommendation.</li>    <li>The firm set its price target at $19, implying a healthy 47.3% upside from curent pricing.</li>    <li>Shares are <font color='red'>down 15.7%</font> YTD after hitting an inflection point in mid-January.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3363959\" data-linked=\"RigNet +2.4% as Maxim gives it a Buy\" data-tweet=\"$RNET - RigNet +2.4% as Maxim gives it a Buy https://seekingalpha.com/news/3363959-rignetplus-2_4-maxim-gives-buy?source=tweet\" data-url=\"https://seekingalpha.com/news/3363959-rignetplus-2_4-maxim-gives-buy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:47 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3363957\" data-ts=\"1528987296\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IPCI\" target=\"_blank\">IPCI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3363957-intellipharmaceutics-up-10-ahead-of-possible-reverse-stock-split\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Intellipharmaceutics up 10% ahead of possible reverse stock split</a></h4><ul><li>Thinly traded nano cap Intellipharmaceutics (<a href='https://seekingalpha.com/symbol/IPCI' title='IntelliPharmaCeutics International Inc'>IPCI</a> <font color='green'>+9.9%</font>) is up on modestly higher volume in early trade. Shares have rallied almost&nbsp;<font color='green'>50%</font>&nbsp;since early May.</li><li>No particular news accounts for the action, although the company is working on a plan to regain compliance with Nasdaq's $1 minimum bid price listing requirement, a plan that will almost certainly include a reverse stock split. Last week, the company <a href=\"https://www.sec.gov/Archives/edgar/data/1474835/000165495418006442/ex991000.htm\" target=\"_blank\">announced </a>that it received a non-compliance letter from Nasdaq related to its bid price deficiency, adding that it proactively addressed the issue with the Hearings Panel in mid-May after which it granted the company a further extension to implement a fix.</li></ul><div class=\"tiny-share-widget\" data-id=\"3363957\" data-linked=\"Intellipharmaceutics up 10% ahead of possible reverse stock split\" data-tweet=\"$IPCI - Intellipharmaceutics up 10% ahead of possible reverse stock split https://seekingalpha.com/news/3363957-intellipharmaceutics-up-10-ahead-of-possible-reverse-stock-split?source=tweet\" data-url=\"https://seekingalpha.com/news/3363957-intellipharmaceutics-up-10-ahead-of-possible-reverse-stock-split\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:41 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3363954\" data-ts=\"1528986966\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CLRO\" target=\"_blank\">CLRO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3363954-clearone-down-17-on-q1-miss\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ClearOne down 17% on Q1 miss</a></h4><ul><li>ClearOne (<a href='https://seekingalpha.com/symbol/CLRO' title='ClearOne, Inc.'>CLRO</a> <font color='red'>-17.1%</font>) reported Q1 revenue decrease of 37.6% Y/Y to $7.29M, reflecting an impact of the on-going harm of infringement of ClearOne's patents resulting in slower adoption of next generation professional audio conferencing platform.</li><li>Q1 Overall margins: Gross&nbsp;<font color='red'>declined by 95 bps</font>&nbsp;to 56.2%, operating&nbsp;<font color='red'>fell by 2,900 bps</font>&nbsp;to -33.5% and Adj. EBITDA&nbsp;<font color='red'>fell by 3,014 bps</font>&nbsp;to -24.7%.</li><li>Q1 Expenses: Sales &amp; marketing $2.87M (+4.6% Y/Y), R&amp;D $2.05M (-12.8% Y/Y) and G&amp;A $1.62M (-23.2% Y/Y).</li><li>Company&rsquo;s Board of Directors decided not to renew the repurchase program which terminated in March 2018 and suspend the dividend program.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3363815-clearone-misses-0_25-misses-revenue\" target=\"_blank\">ClearOne misses by $0.25, misses on revenue</a> (June 14)</li></ul><div class=\"tiny-share-widget\" data-id=\"3363954\" data-linked=\"ClearOne down 17% on Q1 miss\" data-tweet=\"$CLRO - ClearOne down 17% on Q1 miss https://seekingalpha.com/news/3363954-clearone-down-17-on-q1-miss?source=tweet\" data-url=\"https://seekingalpha.com/news/3363954-clearone-down-17-on-q1-miss\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:36 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3363955\" data-ts=\"1528986624\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3363955-eia-natural-gas-inventory\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">EIA Natural Gas Inventory</a></h4><ul><li><a href=\"http://ir.eia.gov/ngs/ngs.html\" target=\"_blank\">EIA Natural Gas Inventory:</a>&nbsp;<strong>+96 Bcf</strong>&nbsp;vs. +87 Bcf consensus, +92 Bcf last week.</li><li>Futures&nbsp;<font color='green'>+0.10%</font>&nbsp;to $2.966.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/UNG' title='The United States Natural Gas ETF, LP'>UNG</a>, <a href='https://seekingalpha.com/symbol/DGAZ' title='VelocityShares 3x Inverse Natural Gas ETN'>DGAZ</a>, <a href='https://seekingalpha.com/symbol/UGAZ' title='VelocityShares 3x Long Natural Gas ETN'>UGAZ</a>, <a href='https://seekingalpha.com/symbol/BOIL' title='ProShares Ultra Bloomberg Natural Gas ETF'>BOIL</a>, <a href='https://seekingalpha.com/symbol/KOLD' title='ProShares UltraShort Bloomberg Natural Gas ETF'>KOLD</a>, <a href='https://seekingalpha.com/symbol/UNL' title='The United States 12 Month Natural Gas ETF, LP'>UNL</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3363955\" data-linked=\"EIA Natural Gas Inventory\" data-tweet=\"$UNG $DGAZ $UGAZ - EIA Natural Gas Inventory https://seekingalpha.com/news/3363955-eia-natural-gas-inventory?source=tweet\" data-url=\"https://seekingalpha.com/news/3363955-eia-natural-gas-inventory\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:30 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3363952\" data-ts=\"1528986320\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FAT\" target=\"_blank\">FAT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3363952-fat-brandsminus-6-after-preferred-stock-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FAT Brands -6% after preferred stock offering</a></h4><ul> <li>FAT Brands (NASDAQ:<a href='https://seekingalpha.com/symbol/FAT' title='FAT Brands Inc.'>FAT</a>) is <font color='red'>down 6.36%</font> after announcing details on its $8M preferred stock offering.</li> <li>The company says it entered into a subscription agreement for the issuance and sale of 800 units, with each unit consisting of 100 shares of newly designated Series A fixed rate cumulative preferred stock and a 5-year warrant to purchase 125 shares of common stock  at an exercise price of $8.00 per share.</li>   </ul><div class=\"tiny-share-widget\" data-id=\"3363952\" data-linked=\"FAT Brands -6% after preferred stock offering\" data-tweet=\"$FAT - FAT Brands -6% after preferred stock offering https://seekingalpha.com/news/3363952-fat-brandsminus-6-after-preferred-stock-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3363952-fat-brandsminus-6-after-preferred-stock-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:25 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3363951\" data-ts=\"1528986086\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AGN\" target=\"_blank\">AGN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3363951-allergan-ticks-higher-activist-investors-dial-up-pressure-for-value-boosting-action-shares-up\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Allergan ticks higher as activist investors dial up the pressure for value-boosting action; shares up 2%</a></h4><ul><li>Allergan (<a href='https://seekingalpha.com/symbol/AGN' title='Allergan plc'>AGN</a> <font color='green'>+2.2%</font>) adds to its rally, albeit on below-average volume. Shares have jumped over&nbsp;<font color='green'>13%</font>&nbsp;in a week after activist investor Carl Icahn established a small stake.</li><li>On Tuesday, another heavyweight investor, David Tepper, sent a \"sternly worded\" <a href=\"https://www.bloomberg.com/news/articles/2018-06-06/icahn-is-said-to-build-small-position-in-drugmaker-allergan\" target=\"_blank\">letter </a>to the board calling its plan to sell its women's health and antibiotic units a \"half-hearted attempt to restore strategic momentum.\" He wants a board shakeup (over and above what the company has done thus far) as a first step to get on track. Senator Investment Group LP managing partner Doug Silverman co-signed the letter.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3363908-allergan-continues-active-board-refreshment-process\" target=\"_blank\">Allergan continues active board refreshment process</a> (June 14)</li></ul><div class=\"tiny-share-widget\" data-id=\"3363951\" data-linked=\"Allergan ticks higher as activist investors dial up the pressure for value-boosting action; shares up 2%\" data-tweet=\"$AGN - Allergan ticks higher as activist investors dial up the pressure for value-boosting action; shares up 2% https://seekingalpha.com/news/3363951-allergan-ticks-higher-activist-investors-dial-up-pressure-for-value-boosting-action-shares-up?source=tweet\" data-url=\"https://seekingalpha.com/news/3363951-allergan-ticks-higher-activist-investors-dial-up-pressure-for-value-boosting-action-shares-up\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:21 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3363948\" data-ts=\"1528985898\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMD\" target=\"_blank\">AMD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3363948-susquehanna-amd-gaining-ryzen-desktop-market-share-mobile-struggles\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Susquehanna: AMD gaining Ryzen desktop market share, Mobile struggles</a></h4><ul><li>        Susquehanna analyst Christopher Rolland <a href=\"https://www.marketwatch.com/story/amd-gaining-share-in-desktop-but-ryzen-mobile-is-still-a-no-show-says-susquehanna-2018-06-14\" target=\"_blank\">says</a> Advanced Micro Devices (NASDAQ:<a href='https://seekingalpha.com/symbol/AMD' title='Advanced Micro Devices, Inc.'>AMD</a>) is gaining share with Ryzen on desktops, but the mobile side is &ldquo;still a no-show.&rdquo;</li><li>                  Rolland cites his data showing AMD with a 15.2% share in desktop CPUs this quarter. Ryzen Mobile held just 0.5% of total laptop share in the second quarter after its launch. AMD Q2 laptop CPU share hit 3.2%, a new low.    </li><li>               Rolland is upbeat on Intel (NASDAQ:<a href='https://seekingalpha.com/symbol/INTC' title='Intel Corporation'>INTC</a>), saying that improving ASPs on the PC side could lead to second quarter upside.&nbsp;</li><li>               AMD shares are&nbsp;<font color='green'>up 1.8%</font>&nbsp;to $16.62.&nbsp;</li><li>               Intel shares are&nbsp;<font color='green'>up 1%</font>&nbsp;to $55.58.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3363948\" data-linked=\"Susquehanna: AMD gaining Ryzen desktop market share, Mobile struggles\" data-tweet=\"$AMD $AMD $INTC - Susquehanna: AMD gaining Ryzen desktop market share, Mobile struggles https://seekingalpha.com/news/3363948-susquehanna-amd-gaining-ryzen-desktop-market-share-mobile-struggles?source=tweet\" data-url=\"https://seekingalpha.com/news/3363948-susquehanna-amd-gaining-ryzen-desktop-market-share-mobile-struggles\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:18 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>137&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3363946\" data-ts=\"1528985587\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AWSM\" target=\"_blank\">AWSM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3363946-time-for-cool-change-infosonics\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Time for a Cool change at InfoSonics</a></h4><ul> <li>InfoSonics (IFON) <font color='green'>rises 7.60%</font> after <a href=\"https://seekingalpha.com/pr/17192114-infosonics-announces-strategic-name-change-cool-holdings-inc\" target=\"_blank\">confirming</a> its name change to Cool Holdings.</li> <li>\"The name change to Cool Holdings represents a shift and diversification of our strategy,\" says InfoSonics Chairman Andy DeFrancesco. \"Effective today our focus is to continue the expansion of our strong partnership with Apple, one of the world's largest and most iconic brands, and to exploit additional investment and acquisition opportunities of minority and majority interests in other premium retail brands to accelerate profitable growth,\" he adds.</li>   </ul><div class=\"tiny-share-widget\" data-id=\"3363946\" data-linked=\"Time for a Cool change at InfoSonics\" data-tweet=\"$AWSM - Time for a Cool change at InfoSonics https://seekingalpha.com/news/3363946-time-for-cool-change-infosonics?source=tweet\" data-url=\"https://seekingalpha.com/news/3363946-time-for-cool-change-infosonics\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:13 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3363938\" data-ts=\"1528985083\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/INTC\" target=\"_blank\">INTC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3363938-intel-started-in-house-chip-production-for-iphones\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Intel has started in-house chip production for iPhones</a></h4><ul><li>           Intel (NASDAQ:<a href='https://seekingalpha.com/symbol/INTC' title='Intel Corporation'>INTC</a>) has <a href=\"https://asia.nikkei.com/Business/Intel-starts-making-modem-chips-for-upcoming-iPhones\" target=\"_blank\">started production</a> of modem chips for this year&rsquo;s Apple iPhones. </li><li> Analysts suspect Intel&rsquo;s XMM 7560 modem chip could secure the majority of iPhone orders while Apple continues its long legal battle with Qualcomm. But Bernstein Research says unspecified quality issues might force Intel to split orders with Qualcomm. </li><li> This year marks the first time Intel is producing the Apple chips in-house after two years of outsourcing production to TSMC. </li><li> Intel shares are&nbsp;<font color='green'>up 1%</font>&nbsp;to $55.58.&nbsp; </li></ul><div class=\"tiny-share-widget\" data-id=\"3363938\" data-linked=\"Intel has started in-house chip production for iPhones\" data-tweet=\"$INTC - Intel has started in-house chip production for iPhones https://seekingalpha.com/news/3363938-intel-started-in-house-chip-production-for-iphones?source=tweet\" data-url=\"https://seekingalpha.com/news/3363938-intel-started-in-house-chip-production-for-iphones\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:04 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>20&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3363936\" data-ts=\"1528984824\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ETSY\" target=\"_blank\">ETSY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3363936-etsyplus-27-to-new-all-time-high\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Etsy +27% to new all-time high</a></h4><ul> <li>Etsy (<a href='https://seekingalpha.com/symbol/ETSY' title='Etsy, Inc.'>ETSY</a> <font color='green'>+26.5%</font>) pops after this morning's announcement of an increase in its base take rate to 5% from 3.5%.</li><li>KeyBanc is out with a positive spin already on the development, calling out the impact for the online retailer.</li> <li>KeyBanc has an Overweight rating and price target of $36 on Etsy.</li> <li>Expect a wave of other analyst to chime in with revisions following the boost in guidance from Etsy.</li><li>Shares of Etsy hit a new all-time high of $42.22 a bit earlier.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3363936\" data-linked=\"Etsy +27% to new all-time high\" data-tweet=\"$ETSY - Etsy +27% to new all-time high https://seekingalpha.com/news/3363936-etsyplus-27-to-new-all-time-high?source=tweet\" data-url=\"https://seekingalpha.com/news/3363936-etsyplus-27-to-new-all-time-high\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:00 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3363934\" data-ts=\"1528984340\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NUS\" target=\"_blank\">NUS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3363934-jefferies-sees-nu-skin-rally-extending\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Jefferies sees Nu Skin rally extending</a></h4><ul> <li>Jefferies starts off coverage on Nu Skin (<a href='https://seekingalpha.com/symbol/NUS' title='Nu Skin Enterprises Inc.'>NUS</a> <font color='green'>+2%</font>) with a <a href=\"https://www.barrons.com/articles/morning-movers-oracle-slips-comcast-gains-kohls-falls-1528982823\" target=\"_blank\">Buy rating</a>.</li> <li>The investment firm assigns a price target of $98 to the beauty products seller.</li> <li>Shares of Nu Skin are already up 22.4% YTD.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3363934\" data-linked=\"Jefferies sees Nu Skin rally extending\" data-tweet=\"$NUS - Jefferies sees Nu Skin rally extending https://seekingalpha.com/news/3363934-jefferies-sees-nu-skin-rally-extending?source=tweet\" data-url=\"https://seekingalpha.com/news/3363934-jefferies-sees-nu-skin-rally-extending\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:52 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3363933\" data-ts=\"1528984168\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KSS\" target=\"_blank\">KSS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3363933-citi-cautious-on-kohls\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Citi cautious on Kohl&#39;s</a></h4><ul> <li>Citi downgrades Kohl's (<a href='https://seekingalpha.com/symbol/KSS' title='Kohl&#39;s Corporation'>KSS</a> <font color='red'>-1.2%</font>) to Neutral from Buy on concerns over traffic .</li> <li>The analyst team gives Kohl's management credit for a number of new initiatives, but sees a balance risk-reward profile on the department store stock at its current level.</li> <li>Shares of Kohl's are up 38% YTD, reaching a high of $79.92 earlier this week.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3363933\" data-linked=\"Citi cautious on Kohl&#39;s\" data-tweet=\"$KSS - Citi cautious on Kohl&#39;s https://seekingalpha.com/news/3363933-citi-cautious-on-kohls?source=tweet\" data-url=\"https://seekingalpha.com/news/3363933-citi-cautious-on-kohls\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:49 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3363922\" data-ts=\"1528982725\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UNIT\" target=\"_blank\">UNIT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3363922-uniti-groupminus-1_7-morgan-stanley-cuts-to-equal-weight\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Uniti Group -1.7% as Morgan Stanley cuts to Equal Weight</a></h4><ul>   <li>Uniti Group (NASDAQ:<a href='https://seekingalpha.com/symbol/UNIT' title='Uniti Group Inc.'>UNIT</a>) is <font color='red'>down 1.7%</font> premarket after a downgrade to Equal Weight by Morgan Stanley.</li>    <li>The firm cut the rating from Overweight, amid a nearly even analyst consensus between Buy and Hold.</li>    <li>Shares in Uniti Group are <font color='green'>up 29.9%</font> YTD, taking advantage of a strong quarter (<font color='green'>up 35.6%</font>); they're <font color='red'>down 13.9%</font> over the span of the past 12 months.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3363922\" data-linked=\"Uniti Group -1.7% as Morgan Stanley cuts to Equal Weight\" data-tweet=\"$UNIT - Uniti Group -1.7% as Morgan Stanley cuts to Equal Weight https://seekingalpha.com/news/3363922-uniti-groupminus-1_7-morgan-stanley-cuts-to-equal-weight?source=tweet\" data-url=\"https://seekingalpha.com/news/3363922-uniti-groupminus-1_7-morgan-stanley-cuts-to-equal-weight\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:25 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>53&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3363917\" data-ts=\"1528982346\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RHT\" target=\"_blank\">RHT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3363917-red-hatplus-1_8-on-barclays-target-boost\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Red Hat +1.8% on Barclays target boost</a></h4><ul><li>           Barclays <a href=\"https://www.streetinsider.com/Analyst+PT+Change/Red+Hat+%28RHT%29+PT+Raised+to+%24186+at+Barclays/14305620.html\" target=\"_blank\">maintains</a> an Overweight rating on Red Hat (NYSE:<a href='https://seekingalpha.com/symbol/RHT' title='Red Hat, Inc.'>RHT</a>) and raises the price target from $170 to $186, a 7% upside to yesterday&rsquo;s close. </li><li> Red Hat shares are&nbsp;<font color='green'>up 1.8%</font>&nbsp;premarket to $177.17.&nbsp; </li></ul><div class=\"tiny-share-widget\" data-id=\"3363917\" data-linked=\"Red Hat +1.8% on Barclays target boost\" data-tweet=\"$RHT - Red Hat +1.8% on Barclays target boost https://seekingalpha.com/news/3363917-red-hatplus-1_8-on-barclays-target-boost?source=tweet\" data-url=\"https://seekingalpha.com/news/3363917-red-hatplus-1_8-on-barclays-target-boost\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:19 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3363911\" data-ts=\"1528981814\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AWSM\" target=\"_blank\">AWSM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3363911-premarket-gainers-of-9-05-06-14-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers as of 9:05 am (06/14/2018)</a></h4><ul><li>IFON <font color='green'>+23%</font>.</li><li><a href='https://seekingalpha.com/symbol/ETSY' title='Etsy, Inc.'>ETSY</a> <font color='green'>+20%</font>.</li><li><a href='https://seekingalpha.com/symbol/DEST' title='Destination Maternity Corporation'>DEST</a> <font color='green'>+19%</font>&nbsp;on Q1 <a href=\"https://seekingalpha.com/news/3363843-destination-maternity-reports-q1-results\" target=\"_blank\">result</a>.</li><li><a href='https://seekingalpha.com/symbol/TLGT' title='Teligent, Inc.'>TLGT</a>&nbsp;<font color='green'>+16%</font>&nbsp;on&nbsp;FDA&nbsp;<a href=\"https://seekingalpha.com/news/3363783-fda-oks-teligents-generic-diflorasone-diacetate-ointment-shares-10-percent-hours\" target=\"_blank\">approval&nbsp;</a>of its generic Diflorasone Diacetate Ointment.</li><li><a href='https://seekingalpha.com/symbol/CTRV' title='ContraVir Pharmaceuticals, Inc.'>CTRV</a>&nbsp;<font color='green'>+10%</font>&nbsp;on to <a href=\"https://seekingalpha.com/news/3363895-contravir-go-start-clinical-development-hbv-candidate-crv431-u-s-shares-14-percent-premarket\" target=\"_blank\">start</a> clinical development of HBV candidate CRV431 in U.S.</li><li><a href='https://seekingalpha.com/symbol/INSY' title='Insys Therapeutics, Inc.'>INSY</a> <font color='green'>+9%</font>.</li><li><a href='https://seekingalpha.com/symbol/BRFS' title='BRF-Brasil Foods S.A.'>BRFS</a> <font color='green'>+9%</font>.</li><li><a href='https://seekingalpha.com/symbol/CODX' title='Co-Diagnostics'>CODX</a> <font color='green'>+6%</font>.</li><li><a href='https://seekingalpha.com/symbol/PVTL' title='Pivotal Software'>PVTL</a> <font color='green'>+6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3363911\" data-linked=\"Premarket Gainers as of 9:05 am (06/14/2018)\" data-tweet=\"$AWSM $AWSM $ETSY - Premarket Gainers as of 9:05 am (06/14/2018) https://seekingalpha.com/news/3363911-premarket-gainers-of-9-05-06-14-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3363911-premarket-gainers-of-9-05-06-14-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:10 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3363910\" data-ts=\"1528981751\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SNOA\" target=\"_blank\">SNOA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3363910-premarket-losers-of-9-05-6-14-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Losers as of 9:05 am (6/14/2018)</a></h4><ul> <li><a href='https://seekingalpha.com/symbol/SNOA' title='Sonoma Pharmaceuticals, Inc.'>SNOA</a>&nbsp;<font color='red'>-21%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3363759-sonoma-pharmaceuticals-misses-0_34-misses-revenue\" target=\"_blank\">Q4 earnings</a>.</li><li><a href='https://seekingalpha.com/symbol/TLRD' title='Tailored Brands, Inc'>TLRD</a>&nbsp;<font color='red'>-16%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3363766-tailored-brands-beats-0_02-beats-revenue\" target=\"_blank\">Q1 earnings</a>.</li><li><a href='https://seekingalpha.com/symbol/FTRPR' title='Frontier Communications Corporation Mand Conv Pfd Shs Series A'>FTRPR</a> <font color='red'>-15%</font>.</li><li><a href='https://seekingalpha.com/symbol/MIK' title='The Michaels Companies'>MIK</a>&nbsp;<font color='red'>-12%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3363847-michaels-companies-beats-0_01-beats-revenue\" target=\"_blank\">Q1 earnings</a>.</li><li><a href='https://seekingalpha.com/symbol/AQMS' title='Aqua Metals'>AQMS</a>&nbsp;<font color='red'>-11%</font>&nbsp;after <a href=\"https://seekingalpha.com/news/3363777-aqua-metals-minus-10-percent-announcing-share-offering\" target=\"_blank\">announcing</a> share offering.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3363910\" data-linked=\"Premarket Losers as of 9:05 am (6/14/2018)\" data-tweet=\"$SNOA $SNOA $TLRD - Premarket Losers as of 9:05 am (6/14/2018) https://seekingalpha.com/news/3363910-premarket-losers-of-9-05-6-14-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3363910-premarket-losers-of-9-05-6-14-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:09 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3363905\" data-ts=\"1528981273\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ASUR\" target=\"_blank\">ASUR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3363905-asure-softwareminus-3_1-after-pricing-share-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Asure Software -3.1% after pricing its share offering</a></h4><ul><li>        Asure Software (NASDAQ:<a href='https://seekingalpha.com/symbol/ASUR' title='Asure Software, Inc.'>ASUR</a>) <a href=\"https://seekingalpha.com/pr/17192235-asure-software-inc-announces-pricing-public-offering-common-stock\" target=\"_blank\">announces</a> the pricing of its public offering at $17.50/share.</li><li>               The offering will include 2M newly issued shares sold by Asure Software and 500K sold by iSystems Holdings.&nbsp;</li><li>               Underwriters have a 30-day option to buy an additional 375K shares.&nbsp;</li><li>               Asure expects 35M in gross proceeds before deducting expenses.&nbsp;</li><li>               Asure Software shares are&nbsp;<font color='red'>down 3.1%</font>&nbsp;premarket to $17.92. &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3363905\" data-linked=\"Asure Software -3.1% after pricing its share offering\" data-tweet=\"$ASUR - Asure Software -3.1% after pricing its share offering https://seekingalpha.com/news/3363905-asure-softwareminus-3_1-after-pricing-share-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3363905-asure-softwareminus-3_1-after-pricing-share-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:01 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3363898\" data-ts=\"1528980073\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NUS\" target=\"_blank\">NUS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3363898-premarket-analyst-action-healthcare\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket analyst action - healthcare</a></h4><ul><li>Nu Skin Enterprises (NYSE:<a href='https://seekingalpha.com/symbol/NUS' title='Nu Skin Enterprises Inc.'>NUS</a>) initiated with Buy rating and $98 (20% upside) price target at Jefferies.</li><li>HealthStream (NASDAQ:<a href='https://seekingalpha.com/symbol/HSTM' title='HealthStream, Inc.'>HSTM</a>) downgraded to Neutral at Robert W. Baird. Shares down&nbsp;<font color='red'>2%</font>&nbsp;premarket.</li></ul><div class=\"tiny-share-widget\" data-id=\"3363898\" data-linked=\"Premarket analyst action - healthcare\" data-tweet=\"$NUS $NUS $HSTM - Premarket analyst action - healthcare https://seekingalpha.com/news/3363898-premarket-analyst-action-healthcare?source=tweet\" data-url=\"https://seekingalpha.com/news/3363898-premarket-analyst-action-healthcare\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:41 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3363895\" data-ts=\"1528979851\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CTRV\" target=\"_blank\">CTRV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3363895-contravir-on-go-to-start-clinical-development-of-hbv-candidate-crv431-in-u-s-shares-up-14\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ContraVir on go to start clinical development of HBV candidate CRV431 in U.S.; shares up 14% premarket</a></h4><ul><li>The FDA has <a href=\"https://seekingalpha.com/pr/17192113-contravir-pharmaceuticals-announces-approval-ind-initiation-clinical-development-program\" target=\"_blank\">signed off</a> on ContraVir Pharmaceuticals' (NASDAQ:<a href='https://seekingalpha.com/symbol/CTRV' title='ContraVir Pharmaceuticals, Inc.'>CTRV</a>) IND for HBV candidate CRV431.</li><li>The company plans to pursue an accelerated clinical program, starting with a Phase 1 study in healthy volunteers to assess the safety, tolerability and pharmacokinetics of single ascending doses, then bridging to a single-dose drug-drug interaction study with Gilead Sciences' (NASDAQ:<a href='https://seekingalpha.com/symbol/GILD' title='Gilead Sciences, Inc.'>GILD</a>) Viread (tenofovir disoproxil fumarate), then to a multi-dose 28-day pilot study in HBV patients.</li><li>CRV431, a next-generation cyclophilin inhibitor, is a non-immunosuppressive analog of cyclosporine A. HBV, HCV and HIV-1 use cyclophilin for replication.</li><li>Shares are up&nbsp;<font color='green'>14%</font>&nbsp;premarket.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3360265-contravirs-crv431-shows-encouraging-action-preclinical-testing-shares-14-percent-premarket\" target=\"_blank\">ContraVir's CRV431 shows encouraging action in preclinical testing; shares up 14% premarket</a> (May 30)</li></ul><div class=\"tiny-share-widget\" data-id=\"3363895\" data-linked=\"ContraVir on go to start clinical development of HBV candidate CRV431 in U.S.; shares up 14% premarket\" data-tweet=\"$CTRV $HEPA $GILD - ContraVir on go to start clinical development of HBV candidate CRV431 in U.S.; shares up 14% premarket https://seekingalpha.com/news/3363895-contravir-on-go-to-start-clinical-development-of-hbv-candidate-crv431-in-u-s-shares-up-14?source=tweet\" data-url=\"https://seekingalpha.com/news/3363895-contravir-on-go-to-start-clinical-development-of-hbv-candidate-crv431-in-u-s-shares-up-14\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:37 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3363883\" data-ts=\"1528978378\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NVAX\" target=\"_blank\">NVAX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3363883-novavaxs-nanoflu-vaccine-improved-immune-responses-in-older-adults-in-phase-1-2-study-shares\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Novavax&#39;s NanoFlu vaccine improved immune responses in older adults in Phase 1/2 study; shares up 3% premarket</a></h4><ul><li>Novavax (NASDAQ:<a href='https://seekingalpha.com/symbol/NVAX' title='Novavax, Inc.'>NVAX</a>) is up&nbsp;<font color='green'>3%</font>&nbsp;premarket on modest volume in response to the <a href=\"https://seekingalpha.com/pr/17191665-new-england-journal-medicine-publishes-novavax-nanoflu-clinical-trial-data\" target=\"_blank\">publication </a>of a peer-reviewed letter in <em>The New England Journal of Medicine</em> detailing the results from a Phase 1/2 clinical trial evaluating seasonal flu vaccine NanoFlu compared to the leading egg-based high-dose vaccine in older adults.</li><li>The letter provides additional data from the announcement made in late February.</li><li>NanoFlu produced antibody titers 28-64% against the homologous and four generations of drifted wild-type A (H3N2) influenza strains and higher antibody titers against the homologous A (H1N1) strain and comparable responses against the homologous B/Brisbane strain.</li><li>NanoFlu is a recombinant hemagglutinin &#40;HA&#41; protein nanoparticle flu vaccine produced by the company's SF9 insect cell baculovirus system. It uses HA amino acid protein sequences that are virtually the same as the wild types. It also contains the adjuvant Matrix-M.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3335352-novavaxs-nanoflu-shows-positive-effect-phase-1-2-study-older-adults-shares-18-percent-hours\" target=\"_blank\">Novavax's NanoFlu shows positive effect in Phase 1/2 study in older adults; shares up 18% after hours</a> (Feb. 28)</li></ul><div class=\"tiny-share-widget\" data-id=\"3363883\" data-linked=\"Novavax&#39;s NanoFlu vaccine improved immune responses in older adults in Phase 1/2 study; shares up 3% premarket\" data-tweet=\"$NVAX - Novavax&#39;s NanoFlu vaccine improved immune responses in older adults in Phase 1/2 study; shares up 3% premarket https://seekingalpha.com/news/3363883-novavaxs-nanoflu-vaccine-improved-immune-responses-in-older-adults-in-phase-1-2-study-shares?source=tweet\" data-url=\"https://seekingalpha.com/news/3363883-novavaxs-nanoflu-vaccine-improved-immune-responses-in-older-adults-in-phase-1-2-study-shares\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:12 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>43&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3363882\" data-ts=\"1528978342\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TAL\" target=\"_blank\">TAL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3363882-tal-education-responds-to-muddy-waters-allegations\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">TAL Education responds to Muddy Waters allegations</a></h4><ul> <li>TAL Education Group (NYSE:<a href='https://seekingalpha.com/symbol/TAL' title='TAL Education Group'>TAL</a>) posts a response to&nbsp;allegations made by Muddy Waters Capital yesterday.</li> <li>\"The allegations made by this short seller contain numerous errors, unsupported speculation and malicious interpretations of events,\" says the company.</li><li>TAL says its board will&nbsp;review the allegations made and consider appropriate actions to protect the interest of its shareholders.</li>  <li>TAL  <font color='red'>-1.90%</font> premarket to  $40.33 after a 10% drop yesterday.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3363677-tal-education-minus-11-percent-muddy-waters-attack\" target=\"_blank\">TAL Education -11% after Muddy Waters attack</a> (June 13)</li><li>Source: <a href=\"https://seekingalpha.com/pr/17191793-tal-education-group-issues-response-deceptive-short-seller-report\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3363882\" data-linked=\"TAL Education responds to Muddy Waters allegations\" data-tweet=\"$TAL - TAL Education responds to Muddy Waters allegations https://seekingalpha.com/news/3363882-tal-education-responds-to-muddy-waters-allegations?source=tweet\" data-url=\"https://seekingalpha.com/news/3363882-tal-education-responds-to-muddy-waters-allegations\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:12 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3363868\" data-ts=\"1528977353\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ARGX\" target=\"_blank\">ARGX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3363868-argenx-announces-data-from-phase-1-study-of-argxminus-113\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Argenx announces data from phase 1 study of ARGX-113</a></h4><ul> <li>Argenx (NASDAQ:<a href='https://seekingalpha.com/symbol/ARGX' title='Argenx SE'>ARGX</a>) <a href=\"https://seekingalpha.com/pr/17191777-argenx-announces-data-phase-1-study-efgartigimod-argxminus-113-subcutaneous-formulation\" target=\"_blank\">announces</a> results from its Phase 1 clinical trial evaluating a subcutaneous &#40;SC&#41; formulation of efgartigimod (ARGX-113) in healthy volunteers.</li>             <li>Results from 32 subjects showed the SC formulation to have comparable half-life, pharmacodynamics and tolerability to the IV formulation and a bioavailability of ~50%. Additionally,&nbsp;initial IV dosing followed by weekly 300 mg SC administration sufficiently maintained IgG suppression at a steady state IgG reduction of ~50%.</li>      <li>Phase 1 study data will be used to further explore SC dosing schedules as a more convenient option for patients.</li>            <li><a href=\"http://www.argenx.com/en-GB/content/argx-113/22/\" target=\"_blank\">Efgartigimod</a> is an antibody fragment designed to block antibody recycling through a receptor called FcRn which induces rapid depletion of autoimmune disease-causing IgG autoantibodies.</li><li>Shares are up&nbsp;<font color='green'>3%</font>&nbsp;premarket.</li>                    </ul><div class=\"tiny-share-widget\" data-id=\"3363868\" data-linked=\"Argenx announces data from phase 1 study of ARGX-113\" data-tweet=\"$ARGX - Argenx announces data from phase 1 study of ARGX-113 https://seekingalpha.com/news/3363868-argenx-announces-data-from-phase-1-study-of-argxminus-113?source=tweet\" data-url=\"https://seekingalpha.com/news/3363868-argenx-announces-data-from-phase-1-study-of-argxminus-113\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:55 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3363871\" data-ts=\"1528977327\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PSTI\" target=\"_blank\">PSTI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3363871-pluristem-to-open-weekly-market-trading-tase\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pluristem to open weekly market trading at TASE</a></h4><ul> <li>Pluristem Therapeutics&nbsp;(NASDAQ:<a href='https://seekingalpha.com/symbol/PSTI' title='Pluristem Therapeutics, Inc.'>PSTI</a>) has been <a href=\"https://seekingalpha.com/pr/17191926-pluristem-open-weekly-market-trading-tase-following-positive-study-results\" target=\"_blank\">invited</a> by the Tel Aviv Stock Exchange &#40;TASE&#41; to open the weekly trading of the Israeli market, following the announcement of its positive study results.</li>     <li>The event will take place at the TASE on June 17 at 9:30am Israel time.</li><li>Shares are down&nbsp;<font color='red'>5%</font>&nbsp;premarket.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3363231-pluristems-plx-pad-cells-successful-mid-stage-ic-study-shares-ahead-14-percent-premarket\" target=\"_blank\">Pluristem's PLX-PAD cells successful in mid-stage IC study; shares ahead 14% premarket</a> (June 12)</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3363871\" data-linked=\"Pluristem to open weekly market trading at TASE\" data-tweet=\"$PSTI - Pluristem to open weekly market trading at TASE https://seekingalpha.com/news/3363871-pluristem-to-open-weekly-market-trading-tase?source=tweet\" data-url=\"https://seekingalpha.com/news/3363871-pluristem-to-open-weekly-market-trading-tase\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:55 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3363869\" data-ts=\"1528977138\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PFE\" target=\"_blank\">PFE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3363869-viiv-healthcares-two-drug-hiv-regimen-successful-in-late-stage-studies-glaxo-up-2-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ViiV Healthcare&#39;s two-drug HIV regimen successful in late-stage studies; Glaxo up 2% premarket</a></h4><ul><li>Two Phase 3 clinical trials, GEMINI-1 &amp; 2, evaluating ViiV Healthcare's two-drug regimen of dolutegravir and lamivudine in adult patients with chronic HIV-1 infection with baseline viral loads less than 500K copies/mL <a href=\"https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-reports-landmark-phase-iii-studies-for-dolutegravir-and-lamivudine-demonstrating-the-ability-to-control-hiv-with-a-two-drug-regimen-in-treatment-na%C3%AFve-patients/\" target=\"_blank\">demonstrated </a>its non-inferiority to the three-drug regimen of dolutegravir, tenofovir disoproxil fumarate and emtricitabine.</li><li>Complete results will be presented at an upcoming scientific conference.</li><li>Global regulatory submissions are on tap for later this year.</li><li>ViiV Healthcare is the HIV-focused joint venture between Pfizer (NYSE:<a href='https://seekingalpha.com/symbol/PFE' title='Pfizer Inc.'>PFE</a>), GlaxoSmithKline (NYSE:<a href='https://seekingalpha.com/symbol/GSK' title='GlaxoSmithKline'>GSK</a>)&nbsp;and Shionogi (<a href=\"https://seekingalpha.com/symbol/SGIOY\" target=\"_blank\">OTCPK:SGIOY</a>)(<a href=\"https://seekingalpha.com/symbol/SGIOF\" target=\"_blank\">OTCPK:SGIOF</a>).</li><li>Glaxo is up&nbsp;<font color='green'>2%</font>&nbsp;premarket while Pfizer is up a fraction.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3358146-viiv-healthcares-hiv-med-juluca-okd-europe\" target=\"_blank\">ViiV Healthcare's HIV med Juluca OK'd in Europe</a> (May 21)</li></ul><div class=\"tiny-share-widget\" data-id=\"3363869\" data-linked=\"ViiV Healthcare&#39;s two-drug HIV regimen successful in late-stage studies; Glaxo up 2% premarket\" data-tweet=\"$PFE $PFE $GSK - ViiV Healthcare&#39;s two-drug HIV regimen successful in late-stage studies; Glaxo up 2% premarket https://seekingalpha.com/news/3363869-viiv-healthcares-two-drug-hiv-regimen-successful-in-late-stage-studies-glaxo-up-2-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3363869-viiv-healthcares-two-drug-hiv-regimen-successful-in-late-stage-studies-glaxo-up-2-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:52 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3363866\" data-ts=\"1528976961\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EXK\" target=\"_blank\">EXK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3363866-endeavour-silver-launches-market-offering-of-up-to-35_7m\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Endeavour Silver launches at-the-market offering of up to $35.7M</a></h4><ul>     <li>Endeavour Silver (NYSE:<a href='https://seekingalpha.com/symbol/EXK' title='Endeavour Silver Corp.'>EXK</a>) <font color='red'>-6.5%</font> premarket after entering into an <a href=\"https://seekingalpha.com/pr/17191684-endeavour-silver-announces-market-offering-us-35_7-million\" target=\"_blank\">at-the-market offering</a> of as much as US$35.7M of common stock.</li>     <li>The company says proceeds from the offering, together with the current cash resources and free cash flow, will be used to advance its  Terronera project and for general corporate purposes.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3363866\" data-linked=\"Endeavour Silver launches at-the-market offering of up to $35.7M\" data-tweet=\"$EXK - Endeavour Silver launches at-the-market offering of up to $35.7M https://seekingalpha.com/news/3363866-endeavour-silver-launches-market-offering-of-up-to-35_7m?source=tweet\" data-url=\"https://seekingalpha.com/news/3363866-endeavour-silver-launches-market-offering-of-up-to-35_7m\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:49 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3363865\" data-ts=\"1528976489\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ORCL\" target=\"_blank\">ORCL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3363865-oracleminus-2_5-jp-morgan-steps-to-sidelines-nomura-lowers-target\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Oracle -2.5% as JP Morgan steps to sidelines, Nomura lowers target</a></h4><ul><li>JP Morgan <a href=\"https://www.streetinsider.com/Analyst+Comments/UPDATE%3A+JPMorgan+Downgrades+Oracle+%28ORCL%29+to+Neutral/14305615.html\" target=\"_blank\">downgrades</a> Oracle (NYSE:<a href='https://seekingalpha.com/symbol/ORCL' title='Oracle Corporation'>ORCL</a>) from Overweight to Neutral and lowers the price target from $55 to $53, a 10% upside to yesterday&rsquo;s close.</li><li>Nomura Instinet <a href=\"https://www.streetinsider.com/Analyst+Comments/Oracle+%28ORCL%29+PT+Lowered+to+%2460+at+NomuraInstinet+Ahead+of+4Q+Release/14305960.html\" target=\"_blank\">lowers</a> Oracle target from $64 to $60 and maintains a Buy rating.</li><li>Oracle shares are&nbsp;<font color='red'>down 2.5%</font>&nbsp;premarket to $47.05.</li><li>Update with more info on the JP Morgan downgrade:</li><li>        Analyst Mark Murphy <a href=\"https://www.cnbc.com/2018/06/14/oracle-shares-drop-after-jp-morgan-downgrades-on-lost-business-to-amazon-and-microsoft.html\" target=\"_blank\">cites</a> the firm&rsquo;s large-scale CIO survey and says Oracle&rsquo;s specific metrics &ldquo;have arced over into negative territory, which makes us uncomfortable because the results of our CIO surveys over the years have been highly predictive.&rdquo;</li><li>               Murphy says that conversations with CIOs show a migration from Oracle databases to Microsoft SQL Server and Amazon databases.&nbsp;</li><li>               The CIO survey includes 154 officers and only 2% called Oracle their &ldquo;most integral&rdquo; cloud computing vendor compared to 27% for Microsoft and 12% for Amazon.&nbsp;&nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3363865\" data-linked=\"Oracle -2.5% as JP Morgan steps to sidelines, Nomura lowers target\" data-tweet=\"$ORCL - Oracle -2.5% as JP Morgan steps to sidelines, Nomura lowers target https://seekingalpha.com/news/3363865-oracleminus-2_5-jp-morgan-steps-to-sidelines-nomura-lowers-target?source=tweet\" data-url=\"https://seekingalpha.com/news/3363865-oracleminus-2_5-jp-morgan-steps-to-sidelines-nomura-lowers-target\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:41 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3363862\" data-ts=\"1528976257\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/APTO\" target=\"_blank\">APTO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3363862-aptose-secures-rights-to-blood-cancer-candidate-in-china-from-crystalgenomics-for-up-to-125m\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aptose secures rights to blood cancer candidate in China from CrystalGenomics for up to $125M; shares up 9% premarket</a></h4><ul><li>Thinly traded micro cap Aptose Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/APTO' title='Aptose Biosciences Inc.'>APTO</a>) is up&nbsp;<font color='green'>9%</font>&nbsp;premarket on light volume in response to its <a href=\"https://seekingalpha.com/pr/17191937-aptose-enters-license-agreement-crystalgenomics-acquire-cgminus-806-rights-china\" target=\"_blank\">announcement </a>that it has inked an agreement with South Korea-based CrystalGenomics for the rights to CG-806 in China, Hong Kong and Macau.</li><li>CG-806 is an orally available small molecule in development for the treatment of acute myeloid leukemia, B-cell malignancies and other blood cancers.</li><li>Under the terms of the deal, Aptose will pay CrystalGenomics $3M upfront, milestones and single-digit royalties on net sales. The total value could reach $125M.</li><li>The transaction extends the agreement announced on May 7 when Aptose exercised its option for an exclusive license to CG-806 worldwide except China and Korea.</li></ul><div class=\"tiny-share-widget\" data-id=\"3363862\" data-linked=\"Aptose secures rights to blood cancer candidate in China from CrystalGenomics for up to $125M; shares up 9% premarket\" data-tweet=\"$APTO - Aptose secures rights to blood cancer candidate in China from CrystalGenomics for up to $125M; shares up 9% premarket https://seekingalpha.com/news/3363862-aptose-secures-rights-to-blood-cancer-candidate-in-china-from-crystalgenomics-for-up-to-125m?source=tweet\" data-url=\"https://seekingalpha.com/news/3363862-aptose-secures-rights-to-blood-cancer-candidate-in-china-from-crystalgenomics-for-up-to-125m\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:37 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3363860\" data-ts=\"1528975925\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MIK\" target=\"_blank\">MIK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3363860-michaelsminus-18-on-soft-profit-view\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Michaels -18% on soft profit view</a></h4><ul> <li>The Michaels Companies (NASDAQ:<a href='https://seekingalpha.com/symbol/MIK' title='The Michaels Companies'>MIK</a>) reports comparable sales increased 0.4% in <a href=\"https://seekingalpha.com/pr/17191892-michaels-companies-announces-first-quarter-2018-results\" target=\"_blank\">Q1</a> to just miss the consensus estimate of +0.8%. A higher average ticket offset a drop in customer transactions during the quarter.</li>  <li>Operating income came in $126.1M vs. $139.3M a year ago.</li> <li>Looking ahead, Michaels expects Q2 EPS of $0.12 to $0.14 vs. $0.19 consensus and full-year EPS of $2.19 to $2.32 vs. $2.32 consensus.</li><li>Shares of Michaels are <font color='red'>down 18%</font> in premarket trading to $18.00.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3363860\" data-linked=\"Michaels -18% on soft profit view\" data-tweet=\"$MIK - Michaels -18% on soft profit view https://seekingalpha.com/news/3363860-michaelsminus-18-on-soft-profit-view?source=tweet\" data-url=\"https://seekingalpha.com/news/3363860-michaelsminus-18-on-soft-profit-view\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:32 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3363847\" data-ts=\"1528974115\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MIK\" target=\"_blank\">MIK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3363847-michaels-companies-beats-0_01-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">The Michaels Companies beats by $0.01, beats on revenue</a></h4><ul><li>The Michaels Companies (NASDAQ:<a href='https://seekingalpha.com/symbol/MIK' title='The Michaels Companies'>MIK</a>): Q1 EPS of $0.39 <font color='green'>beats by $0.01</font>.</li><li>Revenue of $1.16B (flat Y/Y) <font color='green'>beats by $10M</font>.</li><li>Shares <font color='green'>+3.15%</font> PM.</li><li><a href='https://seekingalpha.com/pr/17191892-michaels-companies-announces-first-quarter-2018-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3363847\" data-linked=\"The Michaels Companies beats by $0.01, beats on revenue\" data-tweet=\"$MIK - The Michaels Companies beats by $0.01, beats on revenue https://seekingalpha.com/news/3363847-michaels-companies-beats-0_01-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3363847-michaels-companies-beats-0_01-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:01 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3363833\" data-ts=\"1528971280\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FRED\" target=\"_blank\">FRED</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3363833-freds-positive-post-q1-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fred&#39;s positive post Q1 results</a></h4><ul><li>Fred's (NASDAQ:<a href='https://seekingalpha.com/symbol/FRED' title='Fred&#39;s, Inc.'>FRED</a>) reports comparable-store sales decreased 3.9% in <a href=\"https://seekingalpha.com/pr/17191858-fred-s-reports-first-quarter-2018-results\" target=\"_blank\">Q1</a>.</li><li>Comparable store sales were down 4.3% for the front store, and 3.4% in the retail pharmacy.</li><li>Gross margin rate decreased 220 bps to 25.5%.</li><li>Adjusted SG&amp;A expense rate +10 bps to 28.8%.</li><li>Fred&rsquo;s Interim CEO and CFO,&nbsp;Joe Anto&nbsp;stated, &ldquo;We are rapidly making progress on our two main goals of eliminating our debt balance and returning to significant profitability by Q4 of this year, but there is still much work to be done.&rdquo;</li><li>FRED&nbsp;<font color='green'>+2.86%</font>&nbsp;premarket.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3363831-freds-reports-q1-results\" target=\"_blank\">Fred's reports Q1 results</a> (June 14)</li></ul><div class=\"tiny-share-widget\" data-id=\"3363833\" data-linked=\"Fred&#39;s positive post Q1 results\" data-tweet=\"$FRED - Fred&#39;s positive post Q1 results https://seekingalpha.com/news/3363833-freds-positive-post-q1-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3363833-freds-positive-post-q1-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:14 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":72,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}